

Associations of nonrestorative sleep and insomnia symptoms with incident depressive symptoms over 1–2 years: longitudinal results from the Hispanic Community Health Study/Study of Latinos and Sueño Ancillary Study

Journal:	<i>Depression and Anxiety</i>
Manuscript ID	DA-21-515.R1
Wiley - Manuscript type:	Research Article (Direct Via EEO)
Date Submitted by the Author:	29-Jan-2022
Complete List of Authors:	<p>Saitoh, Kaori; Nihon University School of Medicine, Psychiatry; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders Yoshiike, Takuya; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders Kaneko, Yoshiyuki; Nihon University School of Medicine, Psychiatry Utsumi, Tomohiro; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders; Jikei University School of Medicine, Department of Psychiatry Matsui, Kentaro; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Clinical Laboratory; Tokyo Women’s Medical University, Department of Psychiatry Nagao, Kentaro; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders; National Center of Neurology and Psychiatry, National Center Hospital, Department of Psychiatry; Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences Otsuki, Rei; Nihon University School of Medicine, Psychiatry; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Clinical Laboratory Aritake, Sayaka; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders; Saitama Prefectural University, Department of Health Sciences Kadotani, Hiroshi; Shiga University of Medical Science, Department of Psychiatry Kuriyama, Kenichi; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders; National Center of Neurology and Psychiatry, Department of Psychiatry Suzuki, Masahiro; Nihon University School of Medicine, Psychiatry; National Center of Neurology and Psychiatry National Institute of Mental Health, Department of Sleep-Wake Disorders</p>
Keywords:	mood disorders, sleep disorders, Epidemiology

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Associations of nonrestorative sleep and insomnia symptoms with incident**
7 **depressive symptoms over 1–2 years: longitudinal results from the Hispanic**
8
9 **Community Health Study/Study of Latinos and Sueño Ancillary Study**
10
11
12
13
14
15
16
17
18

19 **Short running title: Incident depressive symptoms and nonrestorative sleep**
20
21
22
23

24 Kaori Saitoh, MD, PhD ^{a, b}; Takuya Yoshiike, MD, PhD ^b; Yoshiyuki Kaneko, MD, PhD ^a;
25
26 Tomohiro Utsumi, MD ^{b, c}; Kentaro Matsui, MD, PhD ^{b, d, f}; Kentaro Nagao, MD ^{b, e, g}; Rei Otsuki,
27
28 MD ^{a, b, d}; Sayaka Aritake, PhD ^{b, h}; Hiroshi Kadotani, MD, PhD ⁱ; Kenichi Kuriyama, MD, PhD ^b;
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

^a *Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan*

^b *Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of
Neurology and Psychiatry, Tokyo, Japan*

^c *Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan*

^d *Department of Clinical Laboratory, National Institute of Mental Health, National Center of
Neurology and Psychiatry, Tokyo, Japan*

1
2
3
4
5
6
7 ^e *Department of Psychiatry, National Center Hospital, National Center of Neurology and*
8
9 *Psychiatry, Tokyo, Japan*

10
11
12 ^f *Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan*

13
14
15 ^g *Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental*
16
17
18 *Sciences, Tokyo Medical and Dental University, Tokyo, Japan*

19
20
21 ^h *Department of Health Sciences, Saitama Prefectural University, Saitama, Japan*

22
23
24 ⁱ *Department of Psychiatry, Shiga University of Medical Science, Shiga, Japan*
25
26
27
28
29
30
31
32

33 Corresponding Author: Masahiro Suzuki, MD, PhD

34
35
36 Department of Psychiatry, Nihon University School of Medicine

37
38
39 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan

40
41
42 Tel: +81 3-3972-8111 (ext. 2431), Fax: +81 3-3972-2920

43
44
45 E-mail address: suzuki.masahiro94@nihon-u.ac.jp
46
47
48
49
50

51 **Acknowledgements**

52
53
54 The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was performed as a
55
56
57 collaborative study supported by contracts from the National Heart, Lung, and Blood Institute
58
59
60

1
2
3
4
5
6 (NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-
7
8
9 HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-
10
11
12 HC65236), and San Diego State University (N01-HC65237) (AG05407, AR35582, AG05394,
13
14
15 AR35584, AR35583, AG08415). The National Sleep Research Resource was supported by the
16
17
18 NHLBI (R24 HL114473, 75N92019R002). We thank Professor Makoto Uchiyama for the helpful
19
20
21 suggestions.

22
23
24 This work was supported by Ministry of Health, Labour and Welfare (19FA1009 and
25
26
27 21FA0201). The funders had no role in the study design, data collection and analysis, decision to
28
29
30 publish, or preparation of the manuscript.
31
32

33 34 35 36 **Disclosures**

37
38
39 Dr. Saitoh has received speaking fees from Yoshitomi Pharmaceutical, outside the submitted
40
41
42 work. Dr. Kaneko has received research grants from Idorsia Pharmaceuticals Japan, outside the
43
44
45 submitted work. Dr. Utsumi reports personal fees from Eisai, outside the submitted work. Dr.
46
47
48 Matsui reports personal fees from Eisai, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical,
49
50
51 Yoshitomi Pharmaceutical and Takeda Pharmaceutical, outside the submitted work. Dr. Aritake-
52
53
54 Okada reports personal fees from Idorsia Pharma and MSD, and grants and personal fees from
55
56
57 Takeda Pharmaceutical, and grants from Kao Corporation, outside the submitted work. Dr.
58
59
60

1
2
3
4
5
6 Kadotani was associated with a laboratory that was supported by donations from Fukuda Lifetech
7
8
9 Co., Ltd., Fukuda Life Tech Keiji Co., Ltd., Tanaka Sleep Clinic, Akita Sleep Clinic, and Ai Care
10
11
12 Co., Ltd. to the Shiga University of Medical Science, outside the submitted work. Dr. Kadotani
13
14
15 received grants from Merck Sharp and Dohme Corp/MSD K.K. (the Investigator-Initiated Studies
16
17
18 Program), Eisai Co., Ltd., and SECOM Science and Technology Foundation, outside the
19
20
21 submitted work. Dr. Kadotani received a consulting fee from Takeda Pharmaceutical Co., Ltd.,
22
23
24 outside the submitted work. Dr. Kuriyama reports research grants from Otsuka Pharmaceutical,
25
26
27 Mitsui Tanabe Pharma, Shionogi Pharma and Pfizer, and research grants and speaker's
28
29
30 honorarium from Meiji Seika Pharma, Eisai, MSD, Takeda Pharmaceutical, Tsumura, and Eli
31
32
33 Lilly, and speaker's honorarium from Yoshitomi Pharmaceutical, outside the submitted work. Dr.
34
35
36 Suzuki has received research grants from Novartis and Shionogi Pharma, research grants and
37
38
39 speaker's honorarium from Dainippon Sumitomo, Eisai, Mochida Pharmaceutical, Otsuka
40
41
42 Pharmaceutical and Takeda Pharmaceutical, and speaker's honorarium from EA Pharma, Meiji
43
44
45 Seika Pharma, MSD, Pfizer, Yoshitomi Pharmaceutical and Viartis, outside the submitted work.
46
47
48 The other authors report no financial relationships with any other commercial interests. The
49
50
51 funders had no role in the design of the study; in the collection, analyses, or interpretation of data;
52
53
54 in the writing of the manuscript; or in the decision to publish the results.
55
56
57
58
59
60

Abstract

Background: Nonrestorative sleep (NRS), defined as insufficiently rested or refreshed sleep, is considered to play an important role in the development of depression. The aim of this study is to investigate the predictive ability of insomnia-related symptoms, including NRS, for incident depressive symptoms (DEPs) in a longitudinal manner.

Methods: We used data of 1196 samples aged 18–64 years who participated in both the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) conducted in 2008–2010 and the follow-up study (Sueño Ancillary Study) conducted in 2010–2013. DEPs and insomnia-related symptoms (difficulty initiating sleep [DIS], difficulty maintaining sleep [DMS], early morning awakening [EMA], difficulty returning to sleep [DRS], and NRS) were evaluated by the 10-item Center for Epidemiologic Studies Depression Scale and the Women’s Health Initiative Insomnia Rating Scale, respectively. A logistic regression analysis was used to evaluate the predictive ability of each insomnia-related symptom at baseline for incident DEPs in couple-years.

Results: In the univariate logistic regression analysis, all insomnia-related symptoms had significant associations with incident DEPs (DIS, odds ratio [OR]=1.6; DMS, OR=1.6; EMA, OR=1.5; DRS, OR=1.9; NRS, OR=2.5). After adjusting for sociodemographic factors and the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

confounding effects of other insomnia-related symptoms, only NRS (OR=2.2, 95% confidence interval=1.4–3.5, p=0.001) was significantly associated with incident DEPs.

Conclusions: NRS was a risk factor for incident DEPs, which includes a predictive ability for other insomnia-related symptoms. Our results suggest that focusing on NRS is an effective strategy for preventing depression in public health promotions.

(242/250 words)

Keywords:

depressive symptoms, insomnia, nonrestorative, sleep, longitudinal, Hispanic, public health

1 Introduction

Depression is one of the greatest social problems (Wong & Licinio, 2001). It is estimated that almost 300 million people around the world are suffering from depression (James et al., 2018; Organization, 2020). This disorder impairs multiple aspects of patient well-being (Kessler et al., 2003) and is a leading cause of suicide, with more than half of suicide cases suffering from depression at the time of death (Hawton & van Heeringen, 2009). Consequently, effective prevention approaches for depression are urgently needed.

Insomnia is widely accepted as one of the risk factors for depression (Baglioni et al., 2011; Li et al., 2016). A recent meta-analysis of 34 cohort studies revealed that people having insomnia were at double the risk of incident depression compared with people without insomnia (Li et al., 2016). A few studies have further tried to identify which basic insomnia symptoms are risk factors for developing depression (Hartz et al., 2007; Yokoyama et al., 2010). Yokoyama et al. (2010) examined the associations between three basic insomnia subtypes (difficulty initiating sleep [DIS], difficulty maintaining sleep [DMS], and early morning awakening [EMA]) and the development of depression 3 years later in the general population aged 65 years and over, and found that DIS was a risk factor for depression.

Nonrestorative sleep (NRS) refers to insufficiently rested or refreshed sleep (Stone et al., 2008). Recently, a growing body of evidence has shown that NRS is associated with various

1
2
3
4
5
6 health problems, including chronic fatigue syndrome, fibromyalgia, heart disease, diabetes, and
7
8
9 gastroesophageal reflux disease (Leineweber et al., 2003; Moldofsky, 1989; Okamoto et al., 2017;
10
11
12 Zhang et al., 2012). Therefore, NRS has recently been attracting attention as a prospective risk
13
14
15 factor of various diseases, although it is not listed as a basic insomnia symptom in the
16
17
18 International Classification of Sleep Disorders, 3rd Edition (American Academy of Sleep
19
20
21 Medicine, 2014).

22
23
24 NRS is considered to play an important role in the development of depression (Stone et
25
26
27 al., 2008). Several studies have shown that NRS is cross-sectionally associated with depression
28
29
30 (Matsumoto et al., 2017; Ohayon, 2005; Roth et al., 2006). Furthermore, NRS was reported to
31
32
33 predict suicide in a longitudinal study in the elderly (Bernert et al., 2014). Given these findings,
34
35
36 NRS could be a possible predictor for incident depression. However, the predictive ability of NRS
37
38
39 for incident depression or depressive symptoms (DEPs) remains unclear.

40
41
42 In this study, we investigated the longitudinal association between insomnia-related
43
44
45 symptoms including NRS for incident DEPs using existing cohort studies among Hispanics or
46
47
48 Latinos living in the USA (Redline et al., 2014; Zhang et al., 2018).

54 **2 Methods**

57 **2.1 Description of the data set**

1
2
3
4
5
6 The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) (Visit 1: V1)
7
8
9 was a community-based cohort study of Hispanic or Latinos living in the USA conducted from
10
11
12 2008 to 2010 at four sites (Bronx, Chicago, Miami, San Diego). The aim of the HCHS/SOL was
13
14
15 to specify protective and harmful factors regarding the health of Hispanics/Latinos. The total
16
17
18 number of participants was 16,415 individuals aged 18–74 years. The details of the HCHS/SOL
19
20
21 sample and design are described elsewhere (LaVange et al., 2010; Sorlie et al., 2010). In that
22
23
24 baseline study, the participants were asked about their physical and mental status with
25
26
27 questionnaires, and underwent several physical tests including a sleep examination (Sorlie et al.,
28
29
30 2010). Most (80%) of the participants were screened for sleep apnea using a home sleep apnea
31
32
33 monitoring system (ARES Unicorder 5.2; B-Alert, Carlsbad, CA, USA).
34
35

36 All participants in V1 who expressed willingness to be contacted for future ancillary
37
38
39 studies, who had no other ancillary tests within the last year, were within 30 months of V1, were
40
41
42 aged 18–64 years, and were able to converse in either English or Spanish were eligible for
43
44
45 recruitment into the Sueño Ancillary Study (Visit 2: V2) (Patel et al., 2015). The exclusion criteria
46
47
48 were having a diagnosis of narcolepsy or sleep apnea by a physician, having been treated with
49
50
51 continuous positive airway pressure or bi-level positive airway pressure, having an apnea–
52
53
54 hypopnea index (AHI) ≥ 50 events per hour at V1, or being a woman who was pregnant. A total
55
56
57 of 4,185 candidates were notified about the V2 study, and their eligibility and willingness to
58
59
60

1
2
3
4
5
6 participate were confirmed. Consequently, 2,252 participants were included in V2; these
7
8
9 participants underwent a reexamination including questionnaires and actigraphy. Among these
10
11
12 participants, 1,912 consented to share their data with external researchers. The average follow-up
13
14
15 period between V1 and V2 was 775 ± 148 days.
16
17

18 Both study protocols were approved by the institutional review boards at each of the
19
20 participating sites. Written informed consent was obtained from all participants. The present study
21
22 was approved by the ethics committee of National Center of Neurology and Psychiatry (A2020-
23
24 012). All analyzed data are publicly available (sleepdata.org).
25
26
27
28
29
30
31
32

33 **2.2 Additional criteria for the present study**

34

35
36 We added the following inclusion criteria for the present study: 1) follow-up period
37
38 between V1 and V2 ≥ 365 days, 2) having successfully answered the question items regarding
39
40 sociodemographic variables, the Women's Health Initiative Insomnia Rating Scale (WHIIRS),
41
42 sleep duration, and sleeping pill use at V1 and the follow-up period, 3) having undergone home
43
44 sleep apnea monitoring to compute AHI at V1, 4) having answered all items on the 10-item Center
45
46 for Epidemiologic Studies Depression Scale (CES-D-10) at both V1 and V2, and 5) having no
47
48 DEPs according to the 9-item Center for Epidemiologic Studies Depression Scale (CES-D-9) at
49
50 V1. Finally, 1196 subjects were included in the present study (Figure 1).
51
52
53
54
55
56
57
58
59
60

2.3 Measures

2.3.1 Incident DEPs

The CES-D-10 was used to assess DEPs (Andresen et al., 1994). This shortened form of the original 20-item version (Radloff, 1977) is composed of 10 items to evaluate DEPs in the past week. Andresen et al. (1994) reported that the cutoff score for DEPs of 16 points on the original version of the CES-D was equivalent to 10 points on the CES-D-10. The validity and reliability of the CES-D-10 have also confirmed among the HCHS/SOL samples (González et al., 2017).

Since the aim of this study was to investigate the relationship between insomnia-related symptoms at baseline and development of DEPs during the study period, the item related sleep (item 7: “My sleep was restless”) was excluded considering a possible bias. Accordingly, we used nine items (CES-D-9) and calculated total scores using the following formula (items 5 and 8 were reverse-coded): total CES-D-9 scores = $\text{SUM}(\text{items 1–6, items 8–10}) \times 10/9$. The cutoff point for DEPs on the CES-D-9 was set at 10 points, the same as the CES-D-10. The participants without DEPs according to the CES-D-9 at both V1 and V2 were defined as non-incident DEPs cases, and those with DEPs at only V2 were defined as incident DEPs cases.

2.3.2 Insomnia-related symptoms

The WHIIRS was used for the assessment of the following five insomnia-related symptoms for the past 4 weeks (Levine et al., 2003):

- 1) DIS: “Did you have trouble falling asleep?”
- 2) DMS: “Did you wake up several times at night?”
- 3) EMA: “Did you wake up earlier than planned?”
- 4) DRS: “Did you have trouble getting back to sleep after you woke up too early?”
- 5) NRS: “Overall, how was your typical night’s sleep during the past 4 weeks?”

There were five response categories for questions 1) through 4): 1, “No, not in the past 4 weeks”; 2, “Yes, less than once a week”; 3, Yes, “1 or 2 times a week”; 4, “Yes, 3 or 4 times a week”; and 5, “Yes, 5 or more times a week”. Those who answered 1 and 2 to the questions were regarded as not having each sleep problem, and those who answered 3 to 5 were regarded as having each sleep problem (Carroll et al., 2017). There were five different answers for question 5): 1, “Very sound or restful”; 2, “Sound or restful”; 3, “Average quality”; 4, “Restless”; and 5, “Very restless”. Those who answered 1–3 to the questions were regarded as having restorative sleep, and those who answered 4 and 5 were regarded as having NRS. The response score on the original version ranged from 0 to 4, whereas the version used in the HCHS/SOL and the Sueño Ancillary Study ranged from 1 to 5. Therefore, WHIIRS total scores were calculated using the

1
2
3
4
5
6 following formula: WHIIRS total scores = DIS + DMS+ EMA + DRS + NRS – 4. Levine et al.
7
8
9 (2003) reported that the internal consistency of the WHIIRS was acceptable ($\alpha = 0.78$) and that
10
11
12 clinically significant insomnia had a cutoff value of 9.
13
14
15
16
17

18 2.3.3 Covariates

20 2.3.3.1 Sociodemographic variables

21
22 The sociodemographic data were evaluated at V1. We treated all sociodemographic
23
24 data as categorical variables, including age (≤ 29 , 30–39, 40–49, 50–59, ≥ 60 years), gender (male,
25
26 female), BMI (< 18.5 , ≥ 18.5 –25, ≥ 25 kg/m²), site (Bronx, Chicago, Miami, San Diego), household
27
28 income ($< 30,000$ USD; $\geq 30,000$ USD; not reported), educational history (less than high school;
29
30 high school and more than high school), marital status (single; married or living with a partner;
31
32 separated, divorced, or widower), alcohol use (never, former, current), and cigarette use (never,
33
34 former, current).
35
36
37
38
39
40
41
42
43
44
45
46
47

48 2.3.3.2 Obstructive sleep apnea (OSA)

49
50
51 The presence of OSA at V1 was examined with a home sleep apnea monitoring device
52
53 (B-Alert). We defined those who had an AHI ≥ 15 as having OSA.
54
55
56
57
58
59
60

2.3.3.3 Sleeping pill use

The following question was used to assess sleeping pill use at V1: “Do you take sleeping pills to help you sleep?” (1, “No, not in the past 4 weeks”; 2, “Yes, less than once a week”; 3, Yes, “1 or 2 times a week”; 4, Yes, “3 or 4 times a week”; 5, Yes, “5 or more times a week”). Those who answered 1 were defined as non-users of sleeping pills, while those who answered 2 to 5 were defined as users of sleeping pills.

2.3.3.4 Sleep duration

Sleep duration was assessed separately for weekdays and weekends using the following questions: “What time do you usually go to bed?” and “What time do you usually wake up?”. After estimating the sleep duration for weekdays and weekends, the average sleep duration for the week was calculated using the following formula: average sleep duration = ([weekend sleep duration] × 2 + [weekday sleep duration] × 5) / 7. We divided sleep duration into five groups (<6; ≥6 to 7; ≥7 to 8; ≥8 to 9; ≥9 hours). Kaneita et al. (2006) reported that sleep duration showed a U-shaped association with depression, with the bottom at 7 hours. Thus, the reference sleep duration was the sleep duration ≥7 to 8 hours group.

2.3.3.5 Follow-up period

1
2
3
4
5
6
7 The follow-up period was classified into two groups (follow-up 1 year: ≥ 365 to 729,
8
9 follow-up 2 years: ≥ 730 days).

15 2.4 Statistical analysis

17
18 The differences in demographic categories between subjects with and without incident
19
20
21 DEPs were examined using the χ^2 test.

22
23
24 The relationship between insomnia-related symptoms and incident DEPs was analyzed
25
26
27 on the basis of univariate and multivariate logistic regression analyses with incident DEPs as a
28
29
30 dependent variable and each insomnia-related symptom at V1 as an independent variable. After
31
32
33 conducting univariate analysis, each insomnia-related symptom at V1 was regressed on incident
34
35
36 DEPs while adjusting for the covariates (age, sex, BMI, center, marital status, alcohol use,
37
38
39 cigarette use, household income, educational history, sleeping pill use, sleep duration, OSA and
40
41
42 follow-up period) (Adjusted 1). We then performed a further multivariate logistic regression
43
44
45 analysis in addition to covariates to assess the confounding effects of other insomnia-related
46
47
48 symptoms (Adjusted 2). The multicollinearity of the insomnia-related symptoms was tested using
49
50
51 the variance inflation factor (VIF). The statistical level of significance was set at $p < 0.05$. All
52
53
54 statistical analyses were conducted using SPSS Statistics ver. 26.0 (IBM, Armonk, NY, USA).

3 Results

3.1 Demographic characteristics and incident DEPs

The demographic characteristics of the entire sample at V1 are shown in Table 1. Females were predominant (60%) and the mean age was 44.4 ± 12.0 years. The average sleep duration was 7.8 ± 1.4 hours. The average follow-up period between V1 and V2 was 785 ± 129 days, and almost 70% of the participants had more than 2 years of follow-up. The average CES-D-9 scores at V1 and V2 were 3.6 ± 2.8 and 5.6 ± 4.9 , respectively. Of the 1196 subjects, 235 (19.6%) had DEPs at V2.

The demographic characteristics of the participants with and without incident DEPs are also shown in Table 1. The prevalence of the incident DEPs was 28% in those who had insomnia at V1, and 16% in those who had no insomnia at V1 ($\chi^2=19.4$, $df=1$, $p<0.001$). In addition to insomnia, incident DEPs was significantly higher in those who were female, were examined in Chicago, had lower education, were current smokers, and used sleeping medication.

3.2 Insomnia-related symptoms

At V1, the mean WHIIRS score was 6.2 ± 5.0 and the prevalence of insomnia was 29.5%. Table 2 shows the prevalence of the five insomnia-related symptoms by gender and age group at V1. DIS was more prevalent in females than in males ($\chi^2=7.9$, $df=1$, $p=0.005$). No gender

1
2
3
4
5
6 differences were found for the other insomnia-related symptoms. The prevalence of DIS ($\chi^2=12.2$,
7
8
9 df=4, $p=0.016$), DMS ($\chi^2=21.5$, df=4, $p<0.0001$), EMA ($\chi^2=14.0$, df=4, $p=0.007$), and DRS
10
11
12 ($\chi^2=21.6$, df=4, $p<0.0001$) significantly differed among the age groups, showing a tendency to be
13
14
15 higher with advanced age. No significant difference was found for NRS by age.
16
17
18
19
20

21 3.3 Association between insomnia-related symptoms and incident DEPs 22 23 24

25 The longitudinal associations between insomnia-related symptoms and incident DEPs
26
27 are shown in Table 3. In the univariate logistic regression analysis, all insomnia-related symptoms
28
29 had significant associations with incident DEPs (DIS, OR=1.6; DMS, OR=1.6; EMA, OR=1.5;
30
31 DRS, OR=1.9; NRS, OR=2.5). After adjusting for covariates (Adjusted 1), the same results were
32
33 obtained. In the multivariate logistic regression analyses adjusted for covariates and the
34
35 confounding effects of other insomnia-related symptoms (Adjusted 2), only NRS (OR=2.2, 95%
36
37 confidence interval=1.4–3.5, $p=0.001$) was significantly associated with incident DEPs. No
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

51 4 Discussion 52 53 54

55 The present study examined the longitudinal associations between insomnia-related
56
57 symptoms (DIS, DMS, EMA, DRS, and NRS) and incident DEPs among Hispanic/Latino adults
58
59
60

1
2
3
4
5
6 in the USA. In the univariate logistic regression analysis, all insomnia-related symptoms showed
7
8
9 significant associations with incident DEPs, even after adjusting for covariates. However, after
10
11
12 adjusting for the confounding effects of other insomnia-related symptoms, only NRS showed a
13
14
15 significant association with incident DEPs. These results suggest that NRS is a risk factor for
16
17
18 incident DEPs, which includes a predictive ability for other insomnia-related symptoms.
19
20
21
22
23
24

25 4.1 Prevalence of insomnia-related symptoms

26
27 In the present study, the prevalence of insomnia as defined by the WHIIRS was 30%,
28
29 which was comparable with that reported in a previous study (Hartz et al., 2007). As for basic
30
31
32 insomnia symptoms, Hartz et al. (2007) summarized the literature on basic insomnia symptoms
33
34 and reported that the prevalence range for each insomnia symptom in the general population (>18
35
36 years of age) was as follows: DIS, 8.3%–23.4%; DMS, 15%–66.7%; and EMA, 9%–18.8%.
37
38
39 While the prevalence of DMS was comparable to that in previous studies, those of DIS and EMA
40
41
42 were higher than those in previous studies (Hartz et al., 2007). The different age and gender
43
44
45 compositions in the present study might be a cause of the higher prevalence of each basic
46
47
48 insomnia symptom.
49
50
51
52
53

54 The prevalence of NRS in this study was 11%, which was comparable with studies in
55
56
57 the European general population (8.9%–10.8%) (Ohayon, 2005; Ohayon & Roth, 2001).
58
59
60

1
2
3
4
5
6 Although we did not find gender and age differences in the prevalence of NRS, some studies have
7
8 reported conflicting findings. In the former European survey, more young adults and women
9
10 complained of NRS compared with older adults and men, respectively (Ohayon, 2005). In another
11
12 general population survey conducted in South Korea, the prevalence of NRS peaked in the age
13
14 group of 25–34 years and was the lowest in the age group of 55–64 years, but no gender difference
15
16 was observed (Ohayon & Hong, 2002). Consequently, gender and age differences in NRS remain
17
18 controversial. These contradictions might be due to methodological differences between studies
19
20 such as sampling and the evaluation of NRS.
21
22
23
24
25
26
27
28
29
30
31
32

33 4.2 Association between basic insomnia symptoms and incident DEPs 34

35
36 The prevalence of incident DEPs in our sample was comparable to a previous report
37
38 that investigated the prevalence of DEPs in the U.S. also using a self-reported questionnaire
39
40 (Wittayanukorn et al., 2014).
41
42
43
44

45 Our study revealed that all insomnia-related symptoms (DIS, DMS, EMA, DRS, and
46
47 NRS) were associated with incident DEPs even after adjusting for covariates. As for basic
48
49 insomnia symptoms (DIS, DMS, and EMA), the ORs were all 1.4. In the previous study, DIS was
50
51 a predictor for DEPs, but not DMS and EMA (Yokoyama et al., 2010). This distinction may be
52
53 due to differences in the participants' ages. While their study was intended for older people, our
54
55
56
57
58
59
60

1
2
3
4
5
6
7 study included participants with a wide age range (18–64 years). Furthermore, we excluded those
8
9 who already had DEPs at baseline, while the previous study did not. This might be another
10
11 explanation for the discrepant results.
12
13
14
15
16
17

18 4.3 NRS as a predictor for incident DEPs 19

20
21 Although NRS is considered to play an important role in the development of depression
22
23 (Matsumoto et al., 2017; Ohayon, 2005; Roth et al., 2006), whether NRS is a cause of depression
24
25 remained unclear. The present study demonstrated that NRS is a risk factor for incident DEPs,
26
27 which includes a predictive ability for other insomnia-related symptoms. Given that NRS is
28
29 reportedly closely associated with daytime dysfunction (Ohayon, 2005; Roth et al., 2006), it may
30
31 reflect daytime dysfunction resulting from insomnia symptoms.
32
33
34
35
36
37
38

39 The finding that NRS was a risk factor for incident DEPs might also be explained by
40
41 the characteristics of sleep architecture in NRS. A previous study on the sleep macrostructure
42
43 reported that subjects with NRS had mean latency to persistent sleep and mean wake after sleep
44
45 onset equivalent to those of healthy volunteers; however, rapid eye movement (REM) sleep and
46
47 stage 3/4 sleep were decreased in subjects with compared with those without NRS (Roth et al.,
48
49 2010). Furthermore, especially in the subjects with NRS who also had symptoms of DIS, DMS
50
51 or both, REM sleep and slow wave sleep decreased remarkably (Roth et al., 2010). REM sleep
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 has been reported to play an important role in regulating emotions such as anxiety and fear by
7
8
9 attenuating the emotional function of the amygdala (van der Helm et al., 2011), and slow wave
10
11
12 sleep has been shown to implicate plasticity in the central nervous system (Tononi & Cirelli, 2006,
13
14
15 2014). These findings suggest that subjects with NRS get less sleep that plays an important role
16
17
18 in regulating rest, emotion, and neural plasticity in the central nervous system, and this might be
19
20
21 associated with the strong predictive ability of NRS for incident DEPs.
22
23

24
25 In addition, a study on the sleep microstructure reported an association between NRS
26
27 and the cyclic alternating pattern (CAP). The CAP is considered to indicate arousal of the central
28
29 nervous system, and is considered to be a solid marker of sleep instability (Parrino et al., 2012;
30
31 Terzano et al., 2001). Terzano et al. (2003) examined the CAP rate in patients with insomnia who
32
33 complained of one of the basic insomnia symptoms together with NRS, and found that the CAP
34
35 rate increased in such patients. Therefore, sleep instability might be associated with both NRS
36
37 and the risk of DEPs.
38
39
40
41
42
43
44
45
46
47

48 4.4 Limitations

49
50
51 Our results should be viewed in light of some methodological limitations. First, our
52
53 sample was relatively small, including only Hispanics/Latinos in the USA, and we enrolled
54
55 subjects up to the age of 64 years. Since the prevalence of depression was high among the elderly,
56
57
58
59
60

1
2
3
4
5
6 future research with a larger sample size and wider age range among other races will be required
7
8
9 to increase the generalizability. Second, this study used subjective sleep assessments. The
10
11
12 observations about NRS should be confirmed with an objective instrument such as actigraphy or
13
14
15 polysomnography. Our findings should be also confirmed in future research using these objective
16
17
18 instruments. Third, we did not consider other possible confounding factors for the association
19
20
21 between sleep-related problems and incident depression, such as caffeine intake and shift work.
22
23
24 Fourth, other diseases related to NRS, such as chronic fatigue syndrome and fibromyalgia, were
25
26
27 not evaluated. Fifth, we used the CES-D for the assessment of depression, and did not actually
28
29
30 treat patients with clinical depression. However, this evaluation of DEPs has been widely used in
31
32
33 many epidemiology studies, and the validity of the CES-D has been sufficiently established. Sixth,
34
35
36 we did not adjust for the increased probability of a Type I error, because this was an exploratory
37
38
39 study.
40
41
42
43
44

45 5 Conclusion

46
47
48 NRS was a risk factor for incident DEPs, which includes a predictive ability for other
49
50
51 insomnia-related symptoms. Our results suggest the importance of focusing on NRS to develop
52
53
54 more effective public health strategies for preventing depression.
55
56
57
58
59
60

1
2
3
4
5
6 (3438/3500 words)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

References

American Academy of Sleep Medicine. (2014). *International Classification of Sleep Disorders* (3rd ed.).

American Academy of Sleep Medicine.

Andresen, E. M., Malmgren, J. A., Carter, W. B., & Patrick, D. L. (1994, Mar-Apr). Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med*, *10*(2), 77-84.

Baglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., Lombardo, C., & Riemann, D. (2011, Dec). Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *J Affect Disord*, *135*(1-3), 10-19.
<https://doi.org/10.1016/j.jad.2011.01.011>

Bernert, R. A., Turvey, C. L., Conwell, Y., & Joiner, T. E., Jr. (2014, Oct). Association of poor subjective sleep quality with risk for death by suicide during a 10-year period: a longitudinal, population-based study of late life. *JAMA Psychiatry*, *71*(10), 1129-1137.
<https://doi.org/10.1001/jamapsychiatry.2014.1126>

1
2
3
4
5
6
7 Carroll, J. E., Irwin, M. R., Levine, M., Seeman, T. E., Absher, D., Assimes, T., & Horvath, S. (2017,
8
9 2017/01/15/). Epigenetic Aging and Immune Senescence in Women With Insomnia Symptoms:
10
11 Findings From the Women's Health Initiative Study. *Biological Psychiatry*, *81*(2), 136-144.
12
13
14
15 <https://doi.org/https://doi.org/10.1016/j.biopsych.2016.07.008>
16
17
18
19
20

21
22 González, P., Nuñez, A., Merz, E., Brintz, C., Weitzman, O., Navas, E. L., Camacho, A., Buelna, C., Penedo,
23
24 F. J., Wassertheil-Smoller, S., Perreira, K., Isasi, C. R., Choca, J., Talavera, G. A., & Gallo, L. C.
25
26
27 (2017). Measurement properties of the Center for Epidemiologic Studies Depression Scale (CES-
28
29 D 10): Findings from HCHS/SOL. *Psychological assessment*, *29*(4), 372-381.
30
31
32
33 <https://doi.org/10.1037/pas0000330>
34
35
36
37
38

39
40 Hartz, A. J., Daly, J. M., Kohatsu, N. D., Stromquist, A. M., Jogerst, G. J., & Kukoyi, O. A. (2007,
41
42 2007/12/01/). Risk Factors for Insomnia in a Rural Population. *Annals of Epidemiology*, *17*(12),
43
44
45 940-947. <https://doi.org/https://doi.org/10.1016/j.annepidem.2007.07.097>
46
47
48
49

50
51
52 Hawton, K., & van Heeringen, K. (2009, Apr 18). Suicide. *Lancet*, *373*(9672), 1372-1381.
53
54
55 [https://doi.org/10.1016/s0140-6736\(09\)60372-x](https://doi.org/10.1016/s0140-6736(09)60372-x)
56
57
58
59
60

1
2
3
4
5
6 James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F.,
7
8
9 Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R. S., Abebe, Z., Abera, S. F., Abil, O. Z.,
10
11
12 Abraha, H. N., Abu-Raddad, L. J., Abu-Rmeileh, N. M. E., Accrombessi, M. M. K., Acharya, D.,
13
14
15 Acharya, P., Ackerman, I. N., Adamu, A. A., Adebayo, O. M., Adekanmbi, V., Adetokunboh, O.
16
17
18 O., Adib, M. G., Adsuar, J. C., Afanvi, K. A., Afarideh, M., Afshin, A., Agarwal, G., Agesa, K. M.,
19
20
21 Aggarwal, R., Aghayan, S. A., Agrawal, S., Ahmadi, A., Ahmadi, M., Ahmadi, H., Ahmed, M.
22
23
24 B., Aichour, A. N., Aichour, I., Aichour, M. T. E., Akinyemiju, T., Akseer, N., Al-Aly, Z., Al-
25
26
27 Eyadhy, A., Al-Mekhlafi, H. M., Al-Raddadi, R. M., Alahdab, F., Alam, K., Alam, T., Alashi, A.,
28
29
30 Alavian, S. M., Alene, K. A., Alijanzadeh, M., Alizadeh-Navaei, R., Aljunid, S. M., Alkerwi, A.
31
32
33 a., Alla, F., Allebeck, P., Alouani, M. M. L., Altirkawi, K., Alvis-Guzman, N., Amare, A. T.,
34
35
36 Aminde, L. N., Ammar, W., Amoako, Y. A., Anber, N. H., Andrei, C. L., Androudi, S., Animut, M.
37
38
39 D., Anjomshoa, M., Ansha, M. G., Antonio, C. A. T., Anwari, P., Arabloo, J., Arauz, A., Aremu,
40
41
42 O., Ariani, F., Armoon, B., Ärnlov, J., Arora, A., Artaman, A., Aryal, K. K., Asayesh, H., Asghar,
43
44
45 R. J., Ataro, Z., Atre, S. R., Ausloos, M., Avila-Burgos, L., Avokpaho, E. F. G. A., Awasthi, A.,
46
47
48 Ayala Quintanilla, B. P., Ayer, R., Azzopardi, P. S., Babazadeh, A., Badali, H., Badawi, A., Bali,
49
50
51 A. G., Ballesteros, K. E., Ballew, S. H., Banach, M., Banoub, J. A. M., Banstola, A., Barac, A.,
52
53
54 Barboza, M. A., Barker-Collo, S. L., Bärnighausen, T. W., Barrero, L. H., Baune, B. T., Bazargan-
55
56
57 Hejazi, S., Bedi, N., Beghi, E., Behzadifar, M., Behzadifar, M., Béjot, Y., Belachew, A. B., Belay,
58
59
60

1
 2
 3
 4
 5
 6 Y. A., Bell, M. L., Bello, A. K., Bensenor, I. M., Bernabe, E., Bernstein, R. S., Beuran, M.,
 7
 8
 9 Beyranvand, T., Bhala, N., Bhattarai, S., Bhaumik, S., Bhutta, Z. A., Biadgo, B., Bijani, A., Bikbov,
 10
 11
 12 B., Bilano, V., Bililign, N., Bin Sayeed, M. S., Bisanzio, D., Blacker, B. F., Blyth, F. M., Bou-Orm,
 13
 14
 15 I. R., Boufous, S., Bourne, R., Brady, O. J., Brainin, M., Brant, L. C., Brazinova, A., Breitborde,
 16
 17
 18 N. J. K., Brenner, H., Briant, P. S., Briggs, A. M., Briko, A. N., Britton, G., Brugha, T., Buchbinder,
 19
 20
 21 R., Busse, R., Butt, Z. A., Cahuana-Hurtado, L., Cano, J., Cárdenas, R., Carrero, J. J., Carter, A.,
 22
 23
 24 Carvalho, F., Castañeda-Orjuela, C. A., Castillo Rivas, J., Castro, F., Catalá-López, F., Cercy, K.
 25
 26
 27 M., Cerin, E., Chaiah, Y., Chang, A. R., Chang, H.-Y., Chang, J.-C., Charlson, F. J., Chattopadhyay,
 28
 29
 30 A., Chattu, V. K., Chaturvedi, P., Chiang, P. P.-C., Chin, K. L., Chitheer, A., Choi, J.-Y. J.,
 31
 32
 33 Chowdhury, R., Christensen, H., Christopher, D. J., Cicuttini, F. M., Ciobanu, L. G., Cirillo, M.,
 34
 35
 36 Claro, R. M., Collado-Mateo, D., Cooper, C., Coresh, J., Cortesi, P. A., Cortinovis, M., Costa, M.,
 37
 38
 39 Cousin, E., Criqui, M. H., Cromwell, E. A., Cross, M., Crump, J. A., Dadi, A. F., Dandona, L.,
 40
 41
 42 Dandona, R., Dargan, P. I., Daryani, A., Das Gupta, R., Das Neves, J., Dasa, T. T., Davey, G.,
 43
 44
 45 Davis, A. C., Davitoliu, D. V., De Courten, B., De La Hoz, F. P., De Leo, D., De Neve, J.-W.,
 46
 47
 48 Degefa, M. G., Degenhardt, L., Deiparine, S., Dellavalle, R. P., Demoz, G. T., Deribe, K., Dervenis,
 49
 50
 51 N., Des Jarlais, D. C., Dessie, G. A., Dey, S., Dharmaratne, S. D., Dinberu, M. T., Dirac, M. A.,
 52
 53
 54 Djalalinia, S., Doan, L., Dokova, K., Doku, D. T., Dorsey, E. R., Doyle, K. E., Driscoll, T. R.,
 55
 56
 57 Dubey, M., Dubljanin, E., Duken, E. E., Duncan, B. B., Duraes, A. R., Ebrahimi, H., Ebrahimpour,
 58
 59
 60

1
2
3
4
5
6 S., Echko, M. M., Edvardsson, D., Effiong, A., Ehrlich, J. R., El Bcheraoui, C., El Sayed Zaki, M.,
7
8
9 El-Khatib, Z., Elkout, H., Elyazar, I. R. F., Enayati, A., Endries, A. Y., Er, B., Erskine, H. E.,
10
11
12 Eshrati, B., Eskandarich, S., Esteghamati, A., Esteghamati, S., Fakhim, H., Fallah Omrani, V.,
13
14
15 Faramarzi, M., Fareed, M., Farhadi, F., Farid, T. A., Farinha, C. S. E. s., Farioli, A., Faro, A., Farvid,
16
17
18 M. S., Farzadfar, F., Feigin, V. L., Fentahun, N., Fereshtehnejad, S.-M., Fernandes, E., Fernandes,
19
20
21 J. C., Ferrari, A. J., Feyissa, G. T., Filip, I., Fischer, F., Fitzmaurice, C., Foigt, N. A., Foreman, K.
22
23
24 J., Fox, J., Frank, T. D., Fukumoto, T., Fullman, N., Fürst, T., Furtado, J. M., Futran, N. D., Gall,
25
26
27 S., Ganji, M., Gankpe, F. G., Garcia-Basteiro, A. L., Gardner, W. M., Gebre, A. K., Gebremedhin,
28
29
30 A. T., Gebremichael, T. G., Gelano, T. F., Geleijnse, J. M., Genova-Maleras, R., Geramo, Y. C. D.,
31
32
33 Gething, P. W., Gezae, K. E., Ghadiri, K., Ghasemi Falavarjani, K., Ghasemi-Kasman, M.,
34
35
36 Ghimire, M., Ghosh, R., Ghoshal, A. G., Giampaoli, S., Gill, P. S., Gill, T. K., Ginawi, I. A.,
37
38
39 Giussani, G., Gnedovskaya, E. V., Goldberg, E. M., Goli, S., Gómez-Dantés, H., Gona, P. N.,
40
41
42 Gopalani, S. V., Gorman, T. M., Goulart, A. C., Goulart, B. N. G., Grada, A., Grams, M. E., Grosso,
43
44
45 G., Gugnani, H. C., Guo, Y., Gupta, P. C., Gupta, R., Gupta, R., Gupta, T., Gyawali, B., Haagsma,
46
47
48 J. A., Hachinski, V., Hafezi-Nejad, N., Haghparast Bidgoli, H., Hagos, T. B., Hailu, G. B., Haj-
49
50
51 Mirzaian, A., Haj-Mirzaian, A., Hamadeh, R. R., Hamidi, S., Handal, A. J., Hankey, G. J., Hao, Y.,
52
53
54 Harb, H. L., Harikrishnan, S., Haro, J. M., Hasan, M., Hassankhani, H., Hassen, H. Y., Havmoeller,
55
56
57 R., Hawley, C. N., Hay, R. J., Hay, S. I., Hedayatizadeh-Omran, A., Heibati, B., Hendrie, D.,
58
59
60

1
2
3
4
5
6 Henok, A., Herteliu, C., Heydarpour, S., Hibstu, D. T., Hoang, H. T., Hoek, H. W., Hoffman, H. J.,
7
8
9 Hole, M. K., Homaie Rad, E., Hoogar, P., Hosgood, H. D., Hosseini, S. M., Hosseinzadeh, M.,
10
11
12 Hostiuc, M., Hostiuc, S., Hotez, P. J., Hoy, D. G., Hsairi, M., Htet, A. S., Hu, G., Huang, J. J.,
13
14
15 Huynh, C. K., Iburg, K. M., Ikeda, C. T., Ileanu, B., Ilesanmi, O. S., Iqbal, U., Irvani, S. S. N.,
16
17
18 Irvine, C. M. S., Islam, S. M. S., Islami, F., Jacobsen, K. H., Jahangiry, L., Jahanmehr, N., Jain, S.
19
20
21 K., Jakovljevic, M., Javanbakht, M., Jayatilleke, A. U., Jeemon, P., Jha, R. P., Jha, V., Ji, J. S.,
22
23
24 Johnson, C. O., Jonas, J. B., Jozwiak, J. J., Jungari, S. B., Jürisson, M., Kabir, Z., Kadel, R., Kahsay,
25
26
27 A., Kalani, R., Kanchan, T., Karami, M., Karami Matin, B., Karch, A., Karema, C., Karimi, N.,
28
29
30 Karimi, S. M., Kasaeian, A., Kassa, D. H., Kassa, G. M., Kassa, T. D., Kassebaum, N. J.,
31
32
33 Katikireddi, S. V., Kawakami, N., Karyani, A. K., Keighobadi, M. M., Keiyoro, P. N., Kemmer,
34
35
36 L., Kemp, G. R., Kengne, A. P., Keren, A., Khader, Y. S., Khafaei, B., Khafaie, M. A., Khajavi, A.,
37
38
39 Khalil, I. A., Khan, E. A., Khan, M. S., Khan, M. A., Khang, Y.-H., Khazaei, M., Khoja, A. T.,
40
41
42 Khosravi, A., Khosravi, M. H., Kiadaliri, A. A., Kiirithio, D. N., Kim, C.-I., Kim, D., Kim, P., Kim,
43
44
45 Y.-E., Kim, Y. J., Kimokoti, R. W., Kinfu, Y., Kisa, A., Kissimova-Skarbek, K., Kivimäki, M.,
46
47
48 Knudsen, A. K. S., Kocarnik, J. M., Kochhar, S., Kokubo, Y., Kolola, T., Kopec, J. A., Kosen, S.,
49
50
51 Kotsakis, G. A., Koul, P. A., Koyanagi, A., Kravchenko, M. A., Krishan, K., Krohn, K. J., Kuate
52
53
54 Defo, B., Kucuk Bicer, B., Kumar, G. A., Kumar, M., Kyu, H. H., Lad, D. P., Lad, S. D., Lafranconi,
55
56
57 A., Laloo, R., Lallukka, T., Lami, F. H., Lansingh, V. C., Latifi, A., Lau, K. M.-M., Lazarus, J. V.,
58
59
60

1
2
3
4
5
6 Leasher, J. L., Ledesma, J. R., Lee, P. H., Leigh, J., Leung, J., Levi, M., Lewycka, S., Li, S., Li,
7
8
9 Y., Liao, Y., Liben, M. L., Lim, L.-L., Lim, S. S., Liu, S., Lodha, R., Looker, K. J., Lopez, A. D.,
10
11
12 Lorkowski, S., Lotufo, P. A., Low, N., Lozano, R., Lucas, T. C. D., Lucchesi, L. R., Lunevicius,
13
14
15 R., Lyons, R. A., Ma, S., Macarayan, E. R. K., Mackay, M. T., Madotto, F., Magdy Abd El Razek,
16
17
18 H., Magdy Abd El Razek, M., Maghavani, D. P., Mahotra, N. B., Mai, H. T., Majdan, M.,
19
20
21 Majdzadeh, R., Majeed, A., Malekzadeh, R., Malta, D. C., Mamun, A. A., Manda, A.-L.,
22
23
24 Manguerra, H., Manhertz, T., Mansournia, M. A., Mantovani, L. G., Mapoma, C. C., Maravilla, J.
25
26
27 C., Marcenes, W., Marks, A., Martins-Melo, F. R., Martopullo, I., März, W., Marzan, M. B.,
28
29
30 Mashamba-Thompson, T. P., Massenburg, B. B., Mathur, M. R., Matsushita, K., Maulik, P. K.,
31
32
33 Mazidi, M., McAlinden, C., McGrath, J. J., McKee, M., Mehndiratta, M. M., Mehrotra, R., Mehta,
34
35
36 K. M., Mehta, V., Mejia-Rodriguez, F., Mekonen, T., Melese, A., Melku, M., Meltzer, M., Memiah,
37
38
39 P. T. N., Memish, Z. A., Mendoza, W., Mengistu, D. T., Mengistu, G., Mensah, G. A., Mereta, S.
40
41
42 T., Meretoja, A., Meretoja, T. J., Mestrovic, T., Mezerji, N. M. G., Miazgowski, B., Miazgowski,
43
44
45 T., Milllear, A. I., Miller, T. R., Miltz, B., Mini, G. K., Mirarefin, M., Mirrakhimov, E. M.,
46
47
48 Misganaw, A. T., Mitchell, P. B., Mitiku, H., Moazen, B., Mohajer, B., Mohammad, K. A.,
49
50
51 Mohammadifard, N., Mohammadnia-Afrouzi, M., Mohammed, M. A., Mohammed, S., Mohebi,
52
53
54 F., Moitra, M., Mokdad, A. H., Molokhia, M., Monasta, L., Moodley, Y., Moosazadeh, M., Moradi,
55
56
57 G., Moradi-Lakeh, M., Moradinazar, M., Moraga, P., Morawska, L., Moreno Velásquez, I.,
58
59
60

1
 2
 3
 4
 5
 6 Morgado-Da-Costa, J., Morrison, S. D., Moschos, M. M., Mountjoy-Venning, W. C., Mousavi, S.
 7
 8
 9 M., Mruts, K. B., Muche, A. A., Muchie, K. F., Mueller, U. O., Muhammed, O. S., Mukhopadhyay,
 10
 11
 12 S., Muller, K., Mumford, J. E., Murhekar, M., Musa, J., Musa, K. I., Mustafa, G., Nabhan, A. F.,
 13
 14
 15 Nagata, C., Naghavi, M., Naheed, A., Nahvijou, A., Naik, G., Naik, N., Najafi, F., Naldi, L., Nam,
 16
 17
 18 H. S., Nangia, V., Nansseu, J. R., Nascimento, B. R., Natarajan, G., Neamati, N., Negroi, I., Negroi,
 19
 20
 21 R. I., Neupane, S., Newton, C. R. J., Ngunjiri, J. W., Nguyen, A. Q., Nguyen, H. T., Nguyen, H. L.
 22
 23
 24 T., Nguyen, H. T., Nguyen, L. H., Nguyen, M., Nguyen, N. B., Nguyen, S. H., Nichols, E.,
 25
 26
 27 Ningrum, D. N. A., Nixon, M. R., Nolutshungu, N., Nomura, S., Norheim, O. F., Noroozi, M.,
 28
 29
 30 Norrving, B., Noubiap, J. J., Nouri, H. R., Nourollahpour Shiadeh, M., Nowroozi, M. R., Nsoesie,
 31
 32
 33 E. O., Nyasulu, P. S., Odell, C. M., Ofori-Asenso, R., Ogbo, F. A., Oh, I.-H., Oladimeji, O.,
 34
 35
 36 Olagunju, A. T., Olagunju, T. O., Olivares, P. R., Olsen, H. E., Olusanya, B. O., Ong, K. L., Ong,
 37
 38
 39 S. K., Oren, E., Ortiz, A., Ota, E., Otstavnov, S. S., Øverland, S., Owolabi, M. O., PA, M., Pacella,
 40
 41
 42 R., Pakpour, A. H., Pana, A., Panda-Jonas, S., Parisi, A., Park, E.-K., Parry, C. D. H., Patel, S.,
 43
 44
 45 Pati, S., Patil, S. T., Patle, A., Patton, G. C., Paturi, V. R., Paulson, K. R., Pearce, N., Pereira, D.
 46
 47
 48 M., Perico, N., Pesudovs, K., Pham, H. Q., Phillips, M. R., Pigott, D. M., Pillay, J. D., Piradov, M.
 49
 50
 51 A., Pirsheeb, M., Pishgar, F., Plana-Ripoll, O., Plass, D., Polinder, S., Popova, S., Postma, M. J.,
 52
 53
 54 Pourshams, A., Poustchi, H., Prabhakaran, D., Prakash, S., Prakash, V., Purcell, C. A., Purwar, M.
 55
 56
 57 B., Qorbani, M., Quistberg, D. A., Radfar, A., Rafay, A., Rafiei, A., Rahim, F., Rahimi, K., Rahimi-
 58
 59
 60

1
2
3
4
5
6 Movaghar, A., Rahimi-Movaghar, V., Rahman, M., Rahman, M. H. u., Rahman, M. A., Rahman,
7
8
9 S. U., Rai, R. K., Rajati, F., Ram, U., Ranjan, P., Ranta, A., Rao, P. C., Rawaf, D. L., Rawaf, S.,
10
11
12 Reddy, K. S., Reiner, R. C., Reinig, N., Reitsma, M. B., Remuzzi, G., Renzaho, A. M. N.,
13
14
15 Resnikoff, S., Rezaei, S., Rezai, M. S., Ribeiro, A. L. P., Roberts, N. L. S., Robinson, S. R., Roever,
16
17
18 L., Ronfani, L., Roshandel, G., Rostami, A., Roth, G. A., Roy, A., Rubagotti, E., Sachdev, P. S.,
19
20
21 Sadat, N., Saddik, B., Sadeghi, E., Sacedi Moghaddam, S., Safari, H., Safari, Y., Safari-Faramani,
22
23
24 R., Safdarian, M., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sahraian, M. A., Sajadi, H. S., Salam,
25
26
27 N., Salama, J. S., Salamati, P., Saleem, K., Saleem, Z., Salimi, Y., Salomon, J. A., Salvi, S. S., Salz,
28
29
30 I., Samy, A. M., Sanabria, J., Sang, Y., Santomauro, D. F., Santos, I. S., Santos, J. V., Santric
31
32
33 Milicevic, M. M., Sao Jose, B. P., Sardana, M., Sarker, A. R., Sarrafzadegan, N., Sartorius, B.,
34
35
36 Sarvi, S., Sathian, B., Satpathy, M., Sawant, A. R., Sawhney, M., Saxena, S., Saylan, M.,
37
38
39 Schaeffner, E., Schmidt, M. I., Schneider, I. J. C., Schöttker, B., Schwebel, D. C., Schwendicke,
40
41
42 F., Scott, J. G., Sekerija, M., Sepanlou, S. G., Serván-Mori, E., Seyedmousavi, S., Shabaninejad,
43
44
45 H., Shafieesabet, A., Shahbazi, M., Shaheen, A. A., Shaikh, M. A., Shams-Beyranvand, M.,
46
47
48 Shamsi, M., Shamsizadeh, M., Sharafi, H., Sharafi, K., Sharif, M., Sharif-Alhoseini, M., Sharma,
49
50
51 M., Sharma, R., She, J., Sheikh, A., Shi, P., Shibuya, K., Shigematsu, M., Shiri, R., Shirkoohi, R.,
52
53
54 Shishani, K., Shiue, I., Shokraneh, F., Shoman, H., Shrime, M. G., Si, S., Siabani, S., Siddiqi, T.
55
56
57 J., Sigfusdottir, I. D., Sigurvinsdottir, R., Silva, J. P., Silveira, D. G. A., Singam, N. S. V., Singh,
58
59
60

1
 2
 3
 4
 5
 6 J. A., Singh, N. P., Singh, V., Sinha, D. N., Skiadaresi, E., Slepak, E. L. N., Sliwa, K., Smith, D.
 7
 8
 9 L., Smith, M., Soares Filho, A. M., Sobaih, B. H., Sobhani, S., Sobngwi, E., Soneji, S. S., Soofi,
 10
 11
 12 M., Soosaraei, M., Sorensen, R. J. D., Soriano, J. B., Soyiri, I. N., Sposato, L. A., Sreeramareddy,
 13
 14
 15 C. T., Srinivasan, V., Stanaway, J. D., Stein, D. J., Steiner, C., Steiner, T. J., Stokes, M. A., Stovner,
 16
 17
 18 L. J., Subart, M. L., Sudaryanto, A., Sufiyani, M. a. B., Sunguya, B. F., Sur, P. J., Sutradhar, I.,
 19
 20
 21 Sykes, B. L., Sylte, D. O., Tabarés-Seisdedos, R., Tadakamadla, S. K., Tadesse, B. T., Tandon, N.,
 22
 23
 24 Tassew, S. G., Tavakkoli, M., Taveira, N., Taylor, H. R., Tehrani-Banihashemi, A., Tekalign, T. G.,
 25
 26
 27 Tekelemedhin, S. W., Tekle, M. G., Temesgen, H., Temsah, M.-H., Temsah, O., Terkawi, A. S.,
 28
 29
 30 Teweldemedhin, M., Thankappan, K. R., Thomas, N., Tilahun, B., To, Q. G., Tonelli, M., Topor-
 31
 32
 33 Madry, R., Topouzis, F., Torre, A. E., Tortajada-Girbés, M., Touvier, M., Tovani-Palone, M. R.,
 34
 35
 36 Towbin, J. A., Tran, B. X., Tran, K. B., Troeger, C. E., Truelsen, T. C., Tsilimbaris, M. K., Tsoi,
 37
 38
 39 D., Tudor Car, L., Tuzcu, E. M., Ukwaja, K. N., Ullah, I., Undurraga, E. A., Unutzer, J., Updike,
 40
 41
 42 R. L., Usman, M. S., Uthman, O. A., Vaduganathan, M., Vaezi, A., Valdez, P. R., Varughese, S.,
 43
 44
 45 Vasankari, T. J., Venketasubramanian, N., Villafaina, S., Violante, F. S., Vladimirov, S. K., Vlassov,
 46
 47
 48 V., Vollset, S. E., Vosoughi, K., Vujcic, I. S., Wagnew, F. S., Waheed, Y., Waller, S. G., Wang, Y.,
 49
 50
 51 Wang, Y.-P., Weiderpass, E., Weintraub, R. G., Weiss, D. J., Weldegebreal, F., Weldegewergs, K.
 52
 53
 54 G., Werdecker, A., West, T. E., Whiteford, H. A., Widecka, J., Wijeratne, T., Wilner, L. B., Wilson,
 55
 56
 57 S., Winkler, A. S., Wiyeh, A. B., Wiysonge, C. S., Wolfe, C. D. A., Woolf, A. D., Wu, S., Wu, Y.-
 58
 59
 60

- 1
2
3
4
5
6 C., Wyper, G. M. A., Xavier, D., Xu, G., Yadgir, S., Yadollahpour, A., Yahyazadeh Jabbari, S. H.,
7
8
9 Yamada, T., Yan, L. L., Yano, Y., Yaseri, M., Yasin, Y. J., Yeshaneh, A., Yimer, E. M., Yip, P.,
10
11
12 Yisma, E., Yonemoto, N., Yoon, S.-J., Yotebieng, M., Younis, M. Z., Yousefifard, M., Yu, C.,
13
14
15 Zadnik, V., Zaidi, Z., Zaman, S. B., Zamani, M., Zare, Z., Zeleke, A. J., Zenebe, Z. M., Zhang, K.,
16
17
18 Zhao, Z., Zhou, M., Zodpey, S., Zucker, I., Vos, T., & Murray, C. J. L. (2018). Global, regional,
19
20
21 and national incidence, prevalence, and years lived with disability for 354 diseases and injuries
22
23
24 for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden
25
26
27 of Disease Study 2017. *The Lancet*, 392(10159), 1789-1858. <https://doi.org/10.1016/S0140->
28
29
30 6736(18)32279-7
31
32
33
34
35
36 Kaneita, Y., Ohida, T., Uchiyama, M., Takemura, S., Kawahara, K., Yokoyama, E., Miyake, T., Harano, S.,
37
38
39 Suzuki, K., & Fujita, T. (2006, Feb). The relationship between depression and sleep disturbances:
40
41
42 a Japanese nationwide general population survey. *J Clin Psychiatry*, 67(2), 196-203.
43
44
45 <https://doi.org/10.4088/jcp.v67n0204>
46
47
48
49
50
51 Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E.,
52
53
54 & Wang, P. S. (2003, Jun 18). The epidemiology of major depressive disorder: results from the
55
56
57 National Comorbidity Survey Replication (NCS-R). *Jama*, 289(23), 3095-3105.
58
59
60

1
2
3
4
5
6 <https://doi.org/10.1001/jama.289.23.3095>
7
8
9
10

11
12 LaVange, L. M., Kalsbeek, W. D., Sorlie, P. D., Avilés-Santa, L. M., Kaplan, R. C., Barnhart, J., Liu, K.,

13
14
15 Giachello, A., Lee, D. J., Ryan, J., Criqui, M. H., & Elder, J. P. (2010, 2010/08/01/). Sample Design
16
17 and Cohort Selection in the Hispanic Community Health Study/Study of Latinos. *Annals of*
18
19 *Epidemiology*, 20(8), 642-649. <https://doi.org/https://doi.org/10.1016/j.annepidem.2010.05.006>
20
21
22
23
24
25

26
27
28 Leineweber, C., Kecklund, G., Janszky, I., Akerstedt, T., & Orth-Gomér, K. (2003, Feb). Poor sleep

29
30 increases the prospective risk for recurrent events in middle-aged women with coronary disease.
31
32 The Stockholm Female Coronary Risk Study. *J Psychosom Res*, 54(2), 121-127.
33
34
35
36 [https://doi.org/10.1016/s0022-3999\(02\)00475-0](https://doi.org/10.1016/s0022-3999(02)00475-0)
37
38
39
40
41

42
43 Levine, D. W., Kripke, D. F., Kaplan, R. M., Lewis, M. A., Naughton, M. J., Bowen, D. J., & Shumaker, S.

44
45 A. (2003, Jun). Reliability and validity of the Women's Health Initiative Insomnia Rating Scale.
46
47
48 *Psychological assessment*, 15(2), 137-148. <https://doi.org/10.1037/1040-3590.15.2.137>
49
50
51
52
53

54
55 Li, L., Wu, C., Gan, Y., Qu, X., & Lu, Z. (2016, Nov 5). Insomnia and the risk of depression: a meta-

56
57 analysis of prospective cohort studies. *BMC Psychiatry*, 16(1), 375.
58
59
60

1
2
3
4
5
6 <https://doi.org/10.1186/s12888-016-1075-3>
7
8
9
10
11

12 Matsumoto, T., Tabara, Y., Murase, K., Takahashi, Y., Setoh, K., Kawaguchi, T., Muro, S., Kadotani, H.,

13
14
15 Kosugi, S., Sekine, A., Yamada, R., Nakayama, T., Mishima, M., Matsuda, F., & Chin, K. (2017).

16
17
18 Combined association of clinical and lifestyle factors with non-restorative sleep: The Nagahama

19
20
21 Study. *PLoS One*, *12*(3), e0171849. <https://doi.org/10.1371/journal.pone.0171849>
22
23
24
25
26
27

28 Moldofsky, H. (1989, Nov). Nonrestorative sleep and symptoms after a febrile illness in patients with

29
30
31 fibrositis and chronic fatigue syndromes. *J Rheumatol Suppl*, *19*, 150-153.
32
33
34
35
36
37

38 Ohayon, M. M. (2005, Jan 10). Prevalence and correlates of nonrestorative sleep complaints. *Arch Intern*

39
40
41 *Med*, *165*(1), 35-41. <https://doi.org/10.1001/archinte.165.1.35>
42
43
44
45
46
47

48 Ohayon, M. M., & Hong, S.-C. (2002, 2002/07/01). Prevalence of insomnia and associated factors in South

49
50
51 Korea. *Journal of Psychosomatic Research*, *53*(1), 593-600.

52
53
54
55
56
57 [https://doi.org/https://doi.org/10.1016/S0022-3999\(02\)00449-X](https://doi.org/https://doi.org/10.1016/S0022-3999(02)00449-X)
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

population? *J Psychosom Res*, 51(6), 745-755. [https://doi.org/10.1016/s0022-3999\(01\)00285-9](https://doi.org/10.1016/s0022-3999(01)00285-9)

Okamoto, M., Kobayashi, Y., Nakamura, F., & Musha, T. (2017, Nov-Dec). Association Between Nonrestorative Sleep and Risk of Diabetes: A Cross-Sectional Study. *Behav Sleep Med*, 15(6), 483-490. <https://doi.org/10.1080/15402002.2016.1163701>

Organization, W. H. (2020, 30 January 2020). *Depression*. Retrieved 1 September from <https://www.who.int/news-room/fact-sheets/detail/depression>

Parrino, L., Ferri, R., Bruni, O., & Terzano, M. G. (2012, Feb). Cyclic alternating pattern (CAP): the marker of sleep instability. *Sleep Med Rev*, 16(1), 27-45. <https://doi.org/10.1016/j.smr.2011.02.003>

Patel, S. R., Weng, J., Rueschman, M., Dudley, K. A., Lored, J. S., Mossavar-Rahmani, Y., Ramirez, M., Ramos, A. R., Reid, K., Seiger, A. N., Sotres-Alvarez, D., Zee, P. C., & Wang, R. (2015, Sep 1). Reproducibility of a Standardized Actigraphy Scoring Algorithm for Sleep in a US Hispanic/Latino Population. *Sleep*, 38(9), 1497-1503. <https://doi.org/10.5665/sleep.4998>

Radloff, L. S. (1977, 1977). The CES-D scale : a self report depression scale for research in the general

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

population. *Appl Psychol Meas*, 1, 385-401. <https://ci.nii.ac.jp/naid/10021821342/>

Redline, S., Sotres-Alvarez, D., Loreda, J., Hall, M., Patel, S. R., Ramos, A., Shah, N., Ries, A., Arens, R.,

Barnhart, J., Youngblood, M., Zee, P., & Daviglius, M. L. (2014, Feb 1). Sleep-disordered breathing

in Hispanic/Latino individuals of diverse backgrounds. The Hispanic Community Health

Study/Study of Latinos. *Am J Respir Crit Care Med*, 189(3), 335-344.

<https://doi.org/10.1164/rccm.201309-1735OC>

Roth, T., Jaeger, S., Jin, R., Kalsekar, A., Stang, P. E., & Kessler, R. C. (2006, Dec 15). Sleep problems,

comorbid mental disorders, and role functioning in the national comorbidity survey replication.

Biol Psychiatry, 60(12), 1364-1371. <https://doi.org/10.1016/j.biopsych.2006.05.039>

Roth, T., Zammit, G., Lankford, A., Mayleben, D., Stern, T., Pitman, V., Clark, D., & Werth, J. L. (2010,

Apr). Nonrestorative sleep as a distinct component of insomnia. *Sleep*, 33(4), 449-458.

<https://doi.org/10.1093/sleep/33.4.449>

Sorlie, P. D., Avilés-Santa, L. M., Wassertheil-Smoller, S., Kaplan, R. C., Daviglius, M. L., Giachello, A. L.,

Schneiderman, N., Raij, L., Talavera, G., Allison, M., LaVange, L., Chambless, L. E., & Heiss, G.

1
2
3
4
5
6 (2010, 2010/08/01/). Design and Implementation of the Hispanic Community Health Study/Study
7
8
9 of Latinos. *Annals of Epidemiology*, 20(8), 629-641.
10
11
12 <https://doi.org/https://doi.org/10.1016/j.annepidem.2010.03.015>
13
14
15
16
17

18 Stone, K. C., Taylor, D. J., McCrae, C. S., Kalsekar, A., & Lichstein, K. L. (2008, Aug). Nonrestorative
19
20
21 sleep. *Sleep Med Rev*, 12(4), 275-288. <https://doi.org/10.1016/j.smrv.2007.12.002>
22
23
24
25
26

27 Terzano, M. G., Parrino, L., Sherieri, A., Chervin, R., Chokroverty, S., Guilleminault, C., Hirshkowitz, M.,
28
29 Mahowald, M., Moldofsky, H., Rosa, A., Thomas, R., & Walters, A. (2001, Nov). Atlas, rules, and
30
31 recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. *Sleep Med*,
32
33
34
35
36
37 2(6), 537-553. [https://doi.org/10.1016/s1389-9457\(01\)00149-6](https://doi.org/10.1016/s1389-9457(01)00149-6)
38
39
40
41

42 Terzano, M. G., Parrino, L., Spaggiari, M. C., Palomba, V., Rossi, M., & Smerieri, A. (2003, Sep). CAP
43
44
45 variables and arousals as sleep electroencephalogram markers for primary insomnia. *Clin*
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Neurophysiol, 114(9), 1715-1723. [https://doi.org/10.1016/s1388-2457\(03\)00136-6](https://doi.org/10.1016/s1388-2457(03)00136-6)

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

62. <https://doi.org/10.1016/j.smrv.2005.05.002>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tononi, G., & Cirelli, C. (2014, Jan 8). Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. *Neuron*, *81*(1), 12-34.

<https://doi.org/10.1016/j.neuron.2013.12.025>

van der Helm, E., Yao, J., Dutt, S., Rao, V., Saletin, J. M., & Walker, M. P. (2011, Dec 6). REM sleep depotentiates amygdala activity to previous emotional experiences. *Curr Biol*, *21*(23), 2029-2032.

<https://doi.org/10.1016/j.cub.2011.10.052>

Wittayanukorn, S., Qian, J., & Hansen, R. A. (2014, May-Jun). Prevalence of depressive symptoms and predictors of treatment among U.S. adults from 2005 to 2010. *Gen Hosp Psychiatry*, *36*(3), 330-

336. <https://doi.org/10.1016/j.genhosppsy.2013.12.009>

Wong, M. L., & Licinio, J. (2001, May). Research and treatment approaches to depression. *Nat Rev*

Neurosci, *2*(5), 343-351. <https://doi.org/10.1038/35072566>

Yokoyama, E., Kaneita, Y., Saito, Y., Uchiyama, M., Matsuzaki, Y., Tamaki, T., Munezawa, T., & Ohida, T. (2010, Dec). Association between depression and insomnia subtypes: a longitudinal study on the

1
2
3
4
5
6 elderly in Japan. *Sleep*, 33(12), 1693-1702. <https://doi.org/10.1093/sleep/33.12.1693>
7
8
9

10
11
12 Zhang, G. Q., Cui, L., Mueller, R., Tao, S., Kim, M., Rueschman, M., Mariani, S., Mobley, D., & Redline,
13
14
15 S. (2018, Oct 1). The National Sleep Research Resource: towards a sleep data commons. *J Am*
16
17
18 *Med Inform Assoc*, 25(10), 1351-1358. <https://doi.org/10.1093/jamia/ocy064>
19
20

21
22
23
24 Zhang, J., Lam, S.-P., Li, S. X., Li, A. M., & Wing, Y.-K. (2012, 2012/06/01/). The longitudinal course and
25
26
27 impact of non-restorative sleep: A five-year community-based follow-up study. *Sleep Medicine*,
28
29
30 *13*(6), 570-576. <https://doi.org/https://doi.org/10.1016/j.sleep.2011.12.012>
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Prevalence of incident depression by participant demographics.

		All (N=1196)		With incident depression (N=235)		Without incident depression (N=961)		Prevalence of depression (%)	p	
		N	(%)	N	(%)	N	(%)			
Insomnia	WHIIRS <9	843	70	138	59	705	73	16%	<0.001	***
	WHIIRS ≥9	353	30	97	41	256	27	28%		
Gender	Men	480	40	79	34	401	42	17%	0.023	*
	Female	716	60	156	66	560	58	22%		
Age (years)	18–29	182	15	34	15	148	15	19%	0.215	
	30–39	172	14	27	12	145	15	16%		
	40–49	375	31	67	29	308	32	18%		
	50–59	371	31	84	36	287	30	23%		
	60–64	96	8	23	10	73	8	24%		
BMI (kg/m ²)	<18.5	9	1	4	2	5	1	44%	0.11	
	≥18.5–25	221	19	48	20	173	18	22%		
	≥25	966	81	183	78	783	82	19%		
Site	Bronx	300	25	62	26	238	25	21%	0.025	*
	Chicago	306	26	76	32	230	24	25%		
	Miami	392	33	63	27	329	34	16%		

		San Diego	198	17	34	15	164	17	17%		
		<30,000	760	64	159	68	601	63	21%	0.073	
	Income (USD)	≥30,000	383	32	62	26	321	33	16%		
		Not reported	53	4	14	6	39	4	26%		
		Less than HS	347	29	90	38	257	27	26%	<0.001	***
	Education	HS and more than HS	849	71	145	62	704	73	17%		
		Single	325	27	65	28	260	27	20%	0.407	
	Marital status	Married or living with a partner	669	56	124	53	545	57	19%		
		Separated, divorced, or widower	202	17	46	19	156	16	23%		
		Never	249	21	55	23	194	20	22%	0.205	
	Alcohol use	Former	392	33	83	35	309	32	21%		
		Current	555	46	97	41	458	48	18%		
		Never	748	63	136	58	612	64	18%	0.002	**
	Cigarette use	Former	246	21	41	17	205	21	17%		
		Current	202	17	58	25	144	15	29%		
		Not, in the past 4 weeks	1063	89	200	85	863	90	19%	0.04	*
	Sleeping medication use	Yes, in the past 4 weeks	133	11	35	15	98	10	26%		
		OSA–	1091	91	216	92	875	91	20%	0.675	
	Obstructive sleep apnea (AHI ≥15)	OSA+	105	9	19	8	86	9	18%		
		<6	78	7	18	8	60	6	23%	0.547	
	Sleep duration (h)	≥6 to 7	189	16	39	17	150	16	21%		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	≥7 to 8	374	31	63	27	311	32	17%	
	≥8 to 9	326	27	69	29	257	27	21%	
	≥9	229	19	46	20	183	19	20%	
Follow-up years	1	386	32	85	36	301	31	22%	0.154
	2	810	68	150	64	660	69	19%	

*p<0.05, **p<0.01, ***p<0.001.

Abbreviations: WHIIRS, Women’s Health Initiative Insomnia Rating Scale; BMI, body mass index; HS, high school; USD, United States dollar; AHI, apnea–hypopnea index.

For Peer Review

Table 2. Prevalence of insomnia-related symptoms by age and gender.

		Difficulty initiating sleep ^{a,b}	Difficulty maintaining sleep ^a	Early morning awakening ^a	Difficulty returning to sleep ^a	Nonrestorative sleep
All	18–29	30%	41%	30%	24%	9%
	30–39	31%	49%	34%	27%	11%
	40–49	32%	49%	38%	26%	12%
	50–59	41%	60%	45%	37%	12%
	60–64	40%	59%	43%	42%	12%
	Total	35%	52%	39%	31%	11%
Male (N=480)	18–29	37%	39%	33%	25%	13%
	30–39	32%	54%	37%	31%	6%
	40–49	29%	47%	43%	28%	10%
	50–59	30%	61%	39%	29%	10%
	60–64	16%	49%	27%	24%	5%
	Total	30%	51%	38%	28%	10%
Female (N=716)	18–29	25%	43%	28%	22%	6%
	30–39	30%	46%	33%	24%	13%
	40–49	33%	51%	35%	26%	13%
	50–59	49%	60%	49%	43%	13%
	60–64	54%	66%	53%	53%	15%
	Total	38%	53%	39%	33%	12%

^asignificantly different among age groups, ^bsignificantly different between genders.

Table 3. Incident depression and insomnia-related symptoms in the logistic regression analysis.

N=1196	Crude OR		Adjusted 1		Adjusted 2	
	(95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Difficulty initiating sleep	1.6 (1.2–2.1)	<0.01 **	1.4 (1.0–1.9)	0.042 *	0.9 (0.6–1.4)	0.699
Difficulty maintaining sleep	1.6 (1.2–2.1)	<0.01 **	1.4 (1.0–1.9)	0.024 *	1.1 (0.8–1.6)	0.501
Early morning awakening	1.5 (1.1–2.0)	<0.01 **	1.4 (1.0–1.9)	0.031 *	1.0 (0.7–1.4)	0.943
Difficulty returning to sleep	1.9 (1.4–2.5)	<0.001 ***	1.8 (1.3–2.4)	<0.001 ***	1.5 (1.0–2.2)	0.071
Nonrestorative sleep	2.5 (1.7–3.7)	<0.001 ***	2.6 (1.7–3.9)	<0.001 ***	2.2 (1.4–3.5)	0.001 **

*p<0.05, **p<0.01, ***p<0.001

Abbreviations: OR, odds ratio; CI, confidence interval.

Adjusted 1: age, gender, BMI (body mass index), field center, annual household income, years of education, marital status, alcohol use, cigarette use, sleep medication use, OSA (obstructive sleep apnea), sleep duration, follow-up years.

Adjusted 2: Adjusted 1 + difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, difficulty returning to sleep, nonrestorative sleep.

1
2
3
4
5
6 Figure Legends
7

8
9 Figure 1. Flowchart of the present study.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Associations of nonrestorative sleep and insomnia symptoms with incident

depressive symptoms over 1–2 years: longitudinal results from the Hispanic

削除: depression

Community Health Study/Study of Latinos and Sueño Ancillary Study

Short running title: Incident depressive symptoms and nonrestorative sleep

削除: A s

削除: depression

Kaori Saitoh, MD, PhD ^{a, b}; Takuya Yoshiike, MD, PhD ^b; Yoshiyuki Kaneko, MD, PhD ^a;

削除:

Tomohiro Utsumi, MD ^{b, c}; Kentaro Matsui, MD, PhD ^{b, d, f}; Kentaro Nagao, MD ^{b, c, g}; Rei Otsuki,

削除:

MD ^{a, b, d}; Sayaka Aritake, PhD ^{b, h}; Hiroshi Kadotani, MD, PhD ⁱ; Kenichi Kuriyama, MD, PhD ^b.

^c; Masahiro Suzuki, MD, PhD ^{a, b}

^a Department of Psychiatry, Nihon University School of Medicine, Tokyo, Japan

^b Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

^c Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan

^d Department of Clinical Laboratory, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

^e *Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan*

^f *Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan*

^g *Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan*

^h *Department of Health Sciences, Saitama Prefectural University, Saitama, Japan*

ⁱ *Department of Psychiatry, Shiga University of Medical Science, Shiga, Japan*

Corresponding Author: Masahiro Suzuki, MD, PhD

Department of Psychiatry, Nihon University School of Medicine,

30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan

Tel: +81 3-3972-8111 (ext. 2431), Fax: +81 3-3972-2920

E-mail address: suzuki.masahiro94@nihon-u.ac.jp

Acknowledgements

[The Hispanic Community Health Study/Study of Latinos \(HCHS/SOL\) was performed as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute](#)

(NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State University (N01-HC65237) (AG05407, AR35582, AG05394, AR35584, AR35583, AG08415). The National Sleep Research Resource was supported by the NHLBI (R24 HL114473, 75N92019R002). We thank Professor Makoto Uchiyama for the helpful suggestions.

This work was supported by Ministry of Health, Labour and Welfare (19FA1009 and 21FA0201). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosures

Dr. Saitoh has received speaking fees from Yoshitomi Pharmaceutical, outside the submitted work. Dr. Kaneko has received research grants from Idorsia Pharmaceuticals Japan, outside the submitted work. Dr. Utsumi reports personal fees from Eisai, outside the submitted work. Dr. Matsui reports personal fees from Eisai, Meiji Seika Pharma, MSD, Otsuka Pharmaceutical, Yoshitomi Pharmaceutical and Takeda Pharmaceutical, outside the submitted work. Dr. Aritake-Okada reports personal fees from Idorsia Pharma and MSD, and grants and personal fees from Takeda Pharmaceutical, and grants from Kao Corporation, outside the submitted work. Dr.

削除: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was supported by the National Heart, Lung, and Blood Institute cooperative agreements with the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State University (N01-HC65237). The following Institutes/Centers/Offices contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Research, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, and the NIH Institution-Office of Dietary Supplements. The National Sleep Research Resource was supported by the National Heart, Lung, and Blood Institute (R24 HL114473, RFP 75N92019R002).

削除: This work was supported by AMED (JP21uk1024004), JSPS KAKENHI (JP20K07956 and JP20K07967), Grants-in-Aid for Scientific Research, Ministry of Health, Labour and Welfare (19FA1009 and 21FA0201), and an Intramural Research Grant (2-1) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry.

削除: ←

削除: .

削除:

1
2
3
4
5
6
7
8
9
10
11
12
13 Kadotani was associated with a laboratory that was supported by donations from Fukuda Lifetech
14 Co., Ltd., Fukuda Life Tech Keiji Co., Ltd., Tanaka Sleep Clinic, Akita Sleep Clinic, and Ai Care
15 Co., Ltd. to the Shiga University of Medical Science, outside the submitted work. Dr. Kadotani
16 received grants from Merck Sharp and Dohme Corp/MSD K.K. (the Investigator-Initiated Studies
17 Program), Eisai Co., Ltd., and SECOM Science and Technology Foundation, outside the
18 submitted work. Dr. Kadotani received a consulting fee from Takeda Pharmaceutical Co., Ltd.,
19 outside the submitted work. Dr. Kuriyama reports research grants from Otsuka Pharmaceutical,
20 Mitsui Tanabe Pharma, Shionogi Pharma and Pfizer, and research grants and speaker's
21 honorarium from Meiji Seika Pharma, Eisai, MSD, Takeda Pharmaceutical, Tsumura, and Eli
22 Lilly, and speaker's honorarium from Yoshitomi Pharmaceutical, outside the submitted work. Dr.
23 Suzuki has received research grants from Novartis and Shionogi Pharma, research grants and
24 speaker's honorarium from Dainippon Sumitomo, Eisai, Mochida Pharmaceutical, Otsuka
25 Pharmaceutical and Takeda Pharmaceutical, and speaker's honorarium from EA Pharma, Meiji
26 Seika Pharma, MSD, Pfizer, Yoshitomi Pharmaceutical and Viatris, outside the submitted work.
27
28 The other authors report no financial relationships with any other commercial interests. The
29 funders had no role in the design of the study; in the collection, analyses, or interpretation of data;
30 in the writing of the manuscript; or in the decision to publish the results.

削除: Dr. Kadotani was associated to a laboratory that was supported by donations from Fukuda Lifetech Co., Ltd., Fukuda Life Tech Keiji Co., Ltd., Tanaka Sleep Clinic, Akita Sleep Clinic, and Ai Care Co., Ltd. To Shiga University of Medical Science, outside the submitted work. Dr. Kadotani received a grant from Merck Sharp and Dohme Corp/MSD K.K. (the Investigator-Initiated Studies Program), outside the submitted work.

削除: and

削除: s

Abstract

Background: Nonrestorative sleep (NRS), defined as insufficiently rested or refreshed sleep, is considered to play an important role in the development of depression. The aim of this study is to investigate the predictive ability of insomnia-related symptoms, including NRS, for incident depressive symptoms (DEPs), in a longitudinal manner.

削除: depression

Methods: We used data of 1196 samples aged 18–64 years who participated in both the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) conducted in 2008–2010 and the follow-up study (Sueño Ancillary Study) conducted in 2010–2013. DEPs and insomnia-related symptoms (difficulty initiating sleep [DIS], difficulty maintaining sleep [DMS], early morning awakening [EMA], difficulty returning to sleep [DRS], and NRS) were evaluated by the 10-item Center for Epidemiologic Studies Depression Scale and the Women’s Health Initiative Insomnia Rating Scale, respectively. A logistic regression analysis was used to evaluate the predictive ability of each insomnia-related symptom at baseline for incident DEPs in couple-years.

削除: Depression

Results: In the univariate logistic regression analysis, all insomnia-related symptoms had significant associations with incident DEPs (DIS, odds ratio, [OR]=1.6; DMS, OR=1.6; EMA, OR=1.5; DRS, OR=1.9; NRS, OR=2.5). After adjusting for sociodemographic factors and the

削除: survey

削除: depression

削除: depression

削除: relative risk

削除: R

削除: R

削除: R

削除: R

削除: R

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

confounding effects of other insomnia-related symptoms, only NRS (OR=2.2, 95% confidence

删除: R

interval=1.4–3.5, $p=0.001$) was significantly associated with incident DEPs.

删除: <

Conclusions: NRS was a risk factor for incident DEPs, which includes a predictive ability for

删除: depression

other insomnia-related symptoms. Our results suggest that focusing on NRS is an effective

删除: depression

strategy for preventing depression in public health promotions.

(242/250 words)

删除: 1

Keywords:

depressive symptoms, insomnia, nonrestorative, sleep, longitudinal, Hispanic, public health

删除: incident

删除: depression

1 Introduction

Depression is one of the greatest social problems (Wong & Licinio, 2001). It is estimated that almost 300 million people around the world are suffering from depression (James et al., 2018; Organization, 2020). This disorder impairs multiple aspects of patient well-being (Kessler et al., 2003) and is a leading cause of suicide, with more than half of suicide cases suffering from depression at the time of death (Hawton & van Heeringen, 2009). Consequently, effective prevention approaches for depression are urgently needed.

Insomnia is widely accepted as one of the risk factors for depression (Baglioni et al., 2011; Li et al., 2016). A recent meta-analysis of 34 cohort studies revealed that people having insomnia were at double the risk of incident depression compared with people without insomnia (Li et al., 2016). A few studies have further tried to identify which basic insomnia symptoms are risk factors for developing depression (Hartz et al., 2007; Yokoyama et al., 2010). Yokoyama et al. (2010) examined the associations between three basic insomnia subtypes (difficulty initiating sleep [DIS], difficulty maintaining sleep [DMS], and early morning awakening [EMA]) and the development of depression 3 years later in the general population aged 65 years and over, and found that DIS was a risk factor for depression.

Nonrestorative sleep (NRS) refers to insufficiently rested or refreshed sleep (Stone et al., 2008). Recently, a growing body of evidence has shown that NRS is associated with various

削除: Yokoyama et al.

削除: (Yokoyama et al., 2010)

削除: (Stone et al., 2008)

1
2
3
4
5
6
7
8
9
10
11
12
13 health problems, including chronic fatigue syndrome, fibromyalgia, heart disease, diabetes, and
14 gastroesophageal reflux disease (Leineweber et al., 2003; Moldofsky, 1989; Okamoto et al., 2017;
15 Zhang et al., 2012). Therefore, NRS has recently been attracting attention as a prospective risk
16 factor of various diseases, although it is not listed as a basic insomnia symptom in the
17 International Classification of Sleep Disorders, 3rd Edition (American Academy of Sleep
18 Medicine, 2014).

書式を変更: 蛍光ペン (なし)

書式を変更: 蛍光ペン (なし)

26 NRS is considered to play an important role in the development of depression (Stone et
27 al., 2008). Several studies have shown that NRS is cross-sectionally associated with depression
28 (Matsumoto et al., 2017; Ohayon, 2005; Roth et al., 2006). Furthermore, NRS was reported to
29 predict suicide in a longitudinal study in the elderly (Bernert et al., 2014). Given these findings,
30 NRS could be a possible predictor for incident depression. However, the predictive ability of NRS
31 for incident depression or depressive symptoms (DEPs) remains unclear.

削除: Given these findings, NRS could be a possible predictor for incident depression. However, no studies have been conducted to examine longitudinally the association between NRS and incident depression.

32
33
34
35
36
37
38
39
40 In this study, we investigated the longitudinal association between insomnia-related
41 symptoms including NRS for incident DEPs using existing cohort studies among Hispanics or
42 Latinos living in the USA (Redline et al., 2014; Zhang et al., 2018).

削除: In this study, we investigated the predictive ability of insomnia-related symptoms (DIS, DMS, EMS, difficulty returning to sleep [DRS], and NRS) for incident depression using existing cohort studies among Hispanics or Latinos living in the USA. Our hypothesis was that NRS would be a stronger predictor than basic insomnia symptoms for the development of depression because NRS is a feeling that could reflect daytime dysfunction resulting from sleep problems, including insomnia.

43 44 45 46 47 48 49 **2 Methods**

50 51 52 53 54 55 56 57 58 59 60 **2.1 Description of the data set**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) (Visit 1: V1)
was a community-based cohort study of Hispanic or Latinos living in the USA conducted from
2008 to 2010 at four sites (Bronx, Chicago, Miami, San Diego). The aim of the HCHS/SOL was
to specify protective and harmful factors regarding the health of Hispanics/Latinos. The total
number of participants was 16,415 individuals aged 18–74 years. The details of the HCHS/SOL
sample and design are described elsewhere (LaVange et al., 2010; Sorlie et al., 2010). In that
baseline study, the participants were asked about their physical and mental status with
questionnaires, and underwent several physical tests including a sleep examination (Sorlie et al.,
2010). Most (80%) of the participants were screened for sleep apnea using a home sleep apnea
monitoring system (ARES Unicorder 5.2; B-Alert, Carlsbad, CA, USA).

All participants in V1 who expressed willingness to be contacted for future ancillary
studies, who had no other ancillary tests within the last year, were within 30 months of V1, were
aged 18–64 years, and were able to converse in either English or Spanish were eligible for
recruitment into the Sueño Ancillary Study (Visit 2: V2) (Patel et al., 2015). The exclusion criteria
were having a diagnosis of narcolepsy or sleep apnea by a physician, having been treated with
continuous positive airway pressure or bi-level positive airway pressure, having an apnea–
hypopnea index (AHI) \geq 50 events per hour at V1, or being a woman who was pregnant. A total
of 4,185 candidates were notified about the V2 study, and their eligibility and willingness to

削除: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) (Visit 1: V1) was conducted from 2008 to 2010. The participants in this multicenter cohort study were Hispanics or Latinos living in the USA. It was conducted at four sites (Bronx, Chicago, Miami, San Diego) that have large Hispanic/Latino communities.

削除: Population-based sampling was used to identify and recruit participants for the HCHS/SOL.

participate were confirmed. Consequently, 2,252 participants were included in V2; these participants underwent a reexamination including questionnaires and actigraphy. Among these participants, 1,912 consented to share their data with external researchers. The average follow-up period between V1 and V2 was 775±148 days.

Both study protocols were approved by the institutional review boards at each of the participating sites. Written informed consent was obtained from all participants. The present study was approved by the ethics committee of National Center of Neurology and Psychiatry (A2020-012). All analyzed data are publicly available (sleepdata.org).

2.2 Additional criteria for the present study

We added the following inclusion criteria for the present study: 1) follow-up period between V1 and V2 ≥ 365 days, 2) having successfully answered the question items regarding sociodemographic variables, the Women's Health Initiative Insomnia Rating Scale (WHIIRS), sleep duration, and sleeping pill use at V1, and the follow-up period, 3) having undergone home sleep apnea monitoring to compute AHI at V1, 4) having answered all items on the 10-item Center for Epidemiologic Studies Depression Scale (CES-D-10) at both V1 and V2, and 5) having no DEPs according to the 9-item Center for Epidemiologic Studies Depression Scale (CES-D-9) at V1. Finally, 1196 subjects were included in the present study (Figure 1).

削除: The total number of participants was 16,415 individuals aged 18–74 years. The details of the HCHS/SOL sample and design are described elsewhere (LaVange et al., 2010; Sorlie et al., 2010).
 The Sueño Ancillary Study (Visit 2: V2) was a follow-up study to the HCHS/SOL conducted from 2010 to 2013. The inclusion criteria for participating in this study were as follows: those who were aged 18–64 years at V2, those who had never been treated for obstructive sleep apnea (OSA), and those who were without an apnea–hypopnea index (AHI) > 50 events per hour at V1 or a narcolepsy diagnosis. Consequently, 2252 individuals were selected to participate in the Sueño Ancillary Study. Participants came to each field center to undergo a reexamination including questionnaires and actigraphy. Finally, data were obtained

削除: (Patel et al., 2015).

削除:

削除: those who had completed the

削除: s

削除: about

削除: age, sex, sites, body mass index (BMI), alcohol use, cigarette use, marital status, income, education history,

削除: ,

削除: days

削除: those who had

削除: those who had

削除: of

削除: those who did not

削除: e

削除: depression

削除: the CES-D-10 at V1.

2.3 Measures

2.3.1 Incident DEPs

The CES-D-10 was used to assess DEPs (Andresen et al., 1994). This shortened form of the original 20-item version (Radloff, 1977) is composed of 10 items to evaluate DEPs in the past week. Andresen et al. (1994) reported that the cutoff score for DEPs of 16 points on the original version of the CES-D was equivalent to 10 points on the CES-D-10. The validity and reliability of the CES-D-10 have also confirmed among the HCHS/SOL samples (González et al., 2017).

Since the aim of this study was to investigate the relationship between insomnia-related symptoms at baseline and development of DEPs during the study period, the item related sleep (item 7: “My sleep was restless”) was excluded considering a possible bias. Accordingly, we used nine items (CES-D-9) and calculated total scores using the following formula (items 5 and 8 were reverse-coded): total CES-D-9 scores = SUM (items 1–6, items 8–10) × 10/9. The cutoff point for DEPs on the CES-D-9 was set at 10 points, the same as the CES-D-10. The participants without DEPs according to the CES-D-9 at both V1 and V2 were defined as non-incident DEPs cases, and those with DEPs at only V2 were defined as incident DEPs cases.

删除: depression

删除: for the assessment of depression.

删除: (the 20-item CES-D)

删除: contains

删除: depression

删除: Andersen et al. (González et al., 2017)

删除: depression

删除: (Andresen et al., 1994)

删除: depression

删除: depression

删除: depression

删除: time points (both

删除:)

删除: depression

删除: depression

删除: depression

2.3.2 Insomnia-related symptoms

The WHIIRS was used for the assessment of the following five insomnia-related symptoms for the past 4 weeks (Levine et al., 2003):

1) DIS: “Did you have trouble falling asleep?”

削除: Difficulty initiating sleep (

2) DMS: “Did you wake up several times at night?”

削除:)

3) EMA: “Did you wake up earlier than planned?”

削除: Difficulty maintaining sleep (

4) DRS: “Did you have trouble getting back to sleep after you woke up too early?”

削除:)

5) NRS: “Overall, how was your typical night’s sleep during the past 4 weeks?”

削除: Early morning awakening (

削除:)

削除: Difficulty returning to sleep (

削除:)

There were five response categories for questions 1) through 4): 1, “No, not in the past 4 weeks”; 2, “Yes, less than once a week”; 3, Yes, “1 or 2 times a week”; 4, “Yes, 3 or 4 times a week”; and 5, “Yes, 5 or more times a week”. Those who answered 1 and 2 to the questions were

削除: Nonrestorative sleep (

削除:)

regarded as not having each sleep problem, and those who answered 3 to 5 were regarded as having each sleep problem (Carroll et al., 2017). There were five different answers for question

削除: ←

5): 1, “Very sound or restful”; 2, “Sound or restful”; 3, “Average quality”; 4, “Restless”; and 5,

“Very restless”. Those who answered 1–3 to the questions were regarded as having restorative

sleep, and those who answered 4 and 5 were regarded as having NRS. The response score on the

original version ranged from 0 to 4, whereas the version used in the HCHS/SOL and the Sueño

Ancillary Study ranged from 1 to 5. Therefore, WHIIRS total scores were calculated using the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

following formula: WHIIRS total scores = DIS + DMS+ EMA + DRS + NRS – 4. [Levine et al.](#)

[\(2003\)](#), reported that the internal consistency of the WHIIRS was acceptable ($\alpha = 0.78$) and that

clinically significant insomnia had a cutoff value of 9.

删除: Levine et al.

删除: (Levine et al., 2003). Previous research has shown that ...

删除: s

删除: point

删除: with the WHIIRS (Levine, Kaplan, et al., 2003; Levine, Kripke, et al., 2003).

2.3.3 Covariates

2.3.3.1 Sociodemographic variables

The sociodemographic data were evaluated at V1. We treated all sociodemographic data as categorical variables, including age (≤ 29 , 30–39, 40–49, 50–59, ≥ 60 years), gender (male, female), BMI (< 18.5 , ≥ 18.5 –25, ≥ 25 kg/m²), site (Bronx, Chicago, Miami, San Diego), household income ($< 30,000$ USD; $\geq 30,000$ USD; not reported), educational history (less than high school; high school and more than high school), marital status (single; married or living with a partner; separated, divorced, or widower), alcohol use (never, former, current), and cigarette use (never, former, current).

2.3.3.2 Obstructive sleep apnea (OSA)

The presence of OSA at V1 was examined with a home sleep apnea monitoring device (B-Alert). We defined those who had an AHI ≥ 15 as having OSA.

删除: ARES Unicorder 5.2;

删除: , Carlsbad, CA

删除: The AHI was calculated, and those who had an AHI ≥ 15 to 50 were defined as having OSA.

2.3.3.3 Sleeping pill use

The following question was used to assess sleeping pill use at V1: “Do you take sleeping pills to help you sleep?” (1, “No, not in the past 4 weeks”; 2, “Yes, less than once a week”; 3, Yes, “1 or 2 times a week”; 4, Yes, “3 or 4 times a week”; 5, Yes, “5 or more times a week”). Those who answered 1 were defined as non-users of sleeping pills, while those who answered 2 to 5 were defined as users of sleeping pills.

2.3.3.4 Sleep duration

Sleep duration was assessed separately for weekdays and weekends using the following questions: “What time do you usually go to bed?” and “What time do you usually wake up?”.

After estimating the sleep duration for weekdays and weekends, the average sleep duration for the week was calculated using the following formula: average sleep duration = ([weekend sleep duration] × 2 + [weekday sleep duration] × 5) / 7. We divided sleep duration into five groups (<6;

≥6 to 7; ≥7 to 8; ≥8 to 9; ≥9 hours). [Kaneita et al. \(2006\)](#), reported that sleep duration showed a U-shaped association with depression, with the bottom at 7 hours. Thus, the reference sleep duration was the sleep duration ≥7 to 8 hours group.

2.3.3.5 Follow-up period

削除: Kaneita et al. (Kaneita et al., 2006)

1
2
3
4
5
6
7
8
9
10
11
12
13 The follow-up period was classified into two groups (follow-up 1 year: ≥ 365 to 729,
14 follow-up 2 years: ≥ 730 days).

20 2.4 Statistical analysis

21 The differences in demographic categories between subjects with and without incident
22 DEPs were examined using the χ^2 test.

23 The relationship between insomnia-related symptoms and incident DEPs was analyzed
24 on the basis of univariate and multivariate logistic regression analyses with incident DEPs as a
25 dependent variable and each insomnia-related symptom at V1 as an independent variable. After
26 conducting univariate analysis, each insomnia-related symptom at V1 was regressed on incident

27 DEPs while adjusting for the covariates (age, sex, BMI, center, marital status, alcohol use,
28 cigarette use, household income, educational history, sleeping pill use, sleep duration, OSA and
29 follow-up period) (Adjusted 1). We then performed a further multivariate logistic regression

30 analysis in addition to covariates to assess the confounding effects of other insomnia-related
31 symptoms (Adjusted 2). The multicollinearity of the insomnia-related symptoms was tested using
32 the variance inflation factor (VIF). The statistical level of significance was set at $p < 0.05$. All
33 statistical analyses were conducted using SPSS Statistics ver. 26.0 (IBM, Armonk, NY, USA).

删除: depression

删除: The Spearman test was performed to assess the correlations among insomnia-related symptoms.

删除: depression

删除: depression

删除: at V2

删除: depression

删除: at V2

删除: sociodemographic factors

删除: , and OSA

删除: sociodemographic factors

3 Results

3.1 Demographic characteristics and incident DEPs

The demographic characteristics of the entire sample at V1 are shown in Table 1. Females were predominant (60%) and the mean age was 44.4±12.0 years. The average sleep duration was 7.8±1.4 hours. The average follow-up period between V1 and V2 was 785±129 days, and almost 70% of the participants had more than 2 years of follow-up. The average CES-D-9 scores at V1 and V2 were 3.6±2.8 and 5.6±4.9, respectively. Of the 1196 subjects, 235 (19.6%) had DEPs at V2.

The demographic characteristics of the participants with and without incident DEPs are also shown in Table 1. The prevalence of the incident DEPs was 28% in those who had insomnia at V1, and 16% in those who had no insomnia at V1 ($\chi^2=19.4$, $df=1$, $p<0.001$). In addition to insomnia, incident DEPs was significantly higher in those who were female, were examined in Chicago, had lower education, were current smokers, and used sleeping medication.

3.2 Insomnia-related symptoms

At V1, the mean WHIIRS score was 6.2±5.0 and the prevalence of insomnia was 29.5%. Table 2 shows the prevalence of the five insomnia-related symptoms by gender and age group at V1. DIS was more prevalent in females than in males ($\chi^2=7.9$, $df=1$, $p=0.005$). No gender

削除: depression

削除: depression

削除: depression

削除: depression

削除: depression

differences were found for the other insomnia-related symptoms. The prevalence of DIS ($\chi^2=12.2$, $df=4$, $p=0.016$), DMS ($\chi^2=21.5$, $df=4$, $p<0.0001$), EMA ($\chi^2=14.0$, $df=4$, $p=0.007$), and DRS ($\chi^2=21.6$, $df=4$, $p<0.0001$) significantly differed among the age groups, showing a tendency to be higher with advanced age. No significant difference was found for NRS by age.

3.3 Association between insomnia-related symptoms and incident DEPs

The longitudinal associations between insomnia-related symptoms and incident DEPs are shown in Table 3. In the univariate logistic regression analysis, all insomnia-related symptoms had significant associations with incident DEPs (DIS, OR=1.6; DMS, OR=1.6; EMA, OR=1.5; DRS, OR=1.9; NRS, OR=2.5). After adjusting for covariates (Adjusted 1), the same results were obtained. In the multivariate logistic regression analyses adjusted for covariates, and the confounding effects of other insomnia-related symptoms (Adjusted 2), only NRS (OR=2.2, 95% confidence interval=1.4–3.5, $p=0.001$) was significantly associated with incident DEPs. No multicollinearity problems were detected for the insomnia-related symptoms (VIF=1.2–1.7).

4 Discussion

The present study examined the longitudinal associations between insomnia-related symptoms (DIS, DMS, EMA, DRS, and NRS) and incident DEPs among Hispanic/Latino adults

删除: 3.3 Correlation among insomnia-related symptoms

The correlations among insomnia-related symptoms are shown in Table 3. In all cases, Spearman's coefficients were <0.7; therefore, the relationships among insomnia subtypes were not considered to be very strong.

删除: 4

删除: depression

删除: depression

删除: 4

删除: depression

删除: relative risk [

删除: R

删除:]

删除: R

删除: R

删除: R

删除: R

删除: sociodemographic variables

删除: sociodemographic factors

删除: R

删除: <

删除: depression

1
2
3
4
5
6
7
8
9
10
11
12
13 in the USA. In the univariate logistic regression analysis, all insomnia-related symptoms showed
14 significant associations with incident DEPs, even after adjusting for covariates. However, after
15 adjusting for the confounding effects of other insomnia-related symptoms, only NRS showed a
16 significant association with incident DEPs. These results suggest that NRS is a risk factor for
17 incident DEPs, which includes a predictive ability for other insomnia-related symptoms.

剷除: The present study aimed to examine the longitudinal associations between insomnia-related symptoms and incident depression in a sample of Hispanic/Latino adults in the USA, and found that not only basic insomnia symptoms, but also NRS, were predictors for the development of depression. Furthermore, in the multivariate analysis adjusted for the confounding effects of other sleep-related symptoms, only NRS showed a significant association with incident depression, suggesting that NRS is a risk factor for depression, which includes a predictive ability for other insomnia-related symptoms.

28 4.1 Prevalence of insomnia-related symptoms

29 In the present study, the prevalence of insomnia as defined by the WHIIRS was 30%,
30 which was comparable with that reported in a previous study (Hartz et al., 2007). As for basic
31 insomnia symptoms, Hartz et al. (2007) summarized the literature on basic insomnia symptoms
32 and reported that the prevalence range for each insomnia symptom in the general population (>18
33 years of age) was as follows: DIS, 8.3%–23.4%; DMS, 15%–66.7%; and EMA, 9%–18.8%.
34 While the prevalence of DMS was comparable to that in previous studies, those of DIS and EMA
35 were higher than those in previous studies (Hartz et al., 2007). The different age and gender
36 compositions in the present study might be a cause of the higher prevalence of each basic
37 insomnia symptom.
38
39
40
41
42
43
44
45
46
47

剷除: (Hartz et al., 2007).

剷除: also

剷除: e

48 The prevalence of NRS in this study was 11%, which was comparable with studies in
49 the European general population (8.9%–10.8%) (Ohayon, 2005; Ohayon & Roth, 2001).
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Although we did not find gender and age differences in the prevalence of NRS, some studies have reported conflicting findings. In the former European survey, more young adults and women complained of NRS compared with older adults and men, respectively (Ohayon, 2005). In another general population survey conducted in South Korea, the prevalence of NRS peaked in the age group of 25–34 years and was the lowest in the age group of 55–64 years, but no gender difference was observed (Ohayon & Hong, 2002). Consequently, gender and age differences in NRS remain controversial. These contradictions might be due to methodological differences between studies such as sampling and the evaluation of NRS.

删除: (Ohayon & Roth, 2001)

删除:

删除: (Ohayon & Partinen, 2002)

4.2 Association between basic insomnia symptoms and incident DEPs

删除: depression

The prevalence of incident DEPs in our sample was comparable to a previous report that investigated the prevalence of DEPs in the U.S. also using a self-reported questionnaire (Wittayanukorn et al., 2014).

Our study revealed that all insomnia-related symptoms (DIS, DMS, EMA, DRS, and NRS) were associated with incident DEPs even after adjusting for covariates. As for basic insomnia symptoms (DIS, DMS, and EMA), the ORs were all 1.4. In the previous study, DIS was a predictor for DEPs, but not DMS and EMA (Yokoyama et al., 2010). This distinction may be due to differences in the participants' ages. While their study was intended for older people, our

删除: depression

删除:

删除: sociodemographic variables

删除: R

删除: conducted by Yokoyama et al.

删除: depression

删除: (Yokoyama et al., 2010)

study included participants with a wide age range (18–64 years). Furthermore, we excluded those who already had DEPs at baseline, while the previous study did not. This might be another explanation for the discrepant results.

删除: of ages

删除: depression

删除: from the analysis

删除: they

4.3 NRS as a predictor for incident DEPs

删除: depression

Although NRS is considered to play an important role in the development of depression (Matsumoto et al., 2017; Ohayon, 2005; Roth et al., 2006), whether NRS is a cause of depression remained unclear. The present study demonstrated that NRS is a risk factor for incident DEPs, which includes a predictive ability for other insomnia-related symptoms. Given that NRS is reportedly closely associated with daytime dysfunction (Ohayon, 2005; Roth et al., 2006), it may reflect daytime dysfunction resulting from insomnia symptoms.

删除: Although NRS is considered to play an important role in the development of depression (Matsumoto et al., 2017; Ohayon, 2005; Roth et al., 2006), it remains unknown whether NRS is a cause of depression. Moreover, the strength of the association remains unclear, especially in comparison with that between insomnia symptoms and depression. The present study highlighted that having NRS can predict incident depression, and that the predictive ability of NRS for incident depression is stronger than that of basic insomnia symptoms. These findings, together with previous studies showing close associations between NRS and daytime dysfunction (Ohayon, 2005; Roth et al., 2006), suggest that NRS may reflect daytime dysfunction accompanied by insomnia symptoms. A decrease in NRS may contribute to psychosomatic recovery and the prevention of depression.⁴²

The finding that NRS was a risk factor for incident DEPs might also be explained by the characteristics of sleep architecture in NRS. A previous study on the sleep macrostructure reported that subjects with NRS had mean latency to persistent sleep and mean wake after sleep onset equivalent to those of healthy volunteers; however, rapid eye movement (REM) sleep and stage 3/4 sleep were decreased in subjects with compared with those without NRS (Roth et al., 2010). Furthermore, especially in the subjects with NRS who also had symptoms of DIS, DMS or both, REM sleep and slow wave sleep decreased remarkably (Roth et al., 2010). REM sleep

删除: The finding in our study that NRS was a strong risk factor for incident depression might be explained by the characteristics of sleep architecture in NRS.

1
2
3
4
5
6
7
8
9
10
11
12
13 has been reported to play an important role in regulating emotions such as anxiety and fear by
14 attenuating the emotional function of the amygdala (van der Helm et al., 2011), and slow wave
15
16 attenuating the emotional function of the amygdala (van der Helm et al., 2011), and slow wave
17
18 sleep has been shown to implicate plasticity in the central nervous system (Tononi & Cirelli, 2006,
19
20 2014). These findings suggest that subjects with NRS get less sleep that plays an important role
21
22 in regulating rest, emotion, and neural plasticity in the central nervous system, and this might be
23
24 associated with the strong predictive ability of NRS for incident DEPs.

削除: depression

25
26
27 In addition, a study on the sleep microstructure reported an association between NRS
28
29 and the cyclic alternating pattern (CAP). The CAP is considered to indicate arousal of the central
30
31 nervous system, and is considered to be a solid marker of sleep instability (Parrino et al., 2012;
32
33 Terzano et al., 2001). Terzano et al. (2003) examined the CAP rate in patients with insomnia who
34
35 complained of one of the basic insomnia symptoms together with NRS, and found that the CAP
36
37 rate increased in such patients. Therefore, sleep instability might be associated with both NRS
38
39 and the risk of DEPs.

削除: Terzano et al.

削除: (Terzano et al., 2003)

削除: depression

44 4.4 Limitations

45
46 Our results should be viewed in light of some methodological limitations. First, our
47
48 sample was relatively small, including only Hispanics/Latinos in the USA, and we enrolled
49
50 subjects up to the age of 64 years. Since the prevalence of depression was high among the elderly,
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13 future research with a larger sample size and wider age range among other races will be required
14
15 to increase the generalizability. Second, this study used subjective sleep assessments. The
16
17 observations about NRS should be confirmed with an objective instrument such as actigraphy or
18
19 polysomnography. Our findings should be also confirmed in future research using these objective
20
21 instruments. Third, we did not consider other possible confounding factors for the association
22
23 between sleep-related problems and incident depression, such as caffeine intake and shift work.
24
25 Fourth, other diseases related to NRS, such as chronic fatigue syndrome and fibromyalgia, were
26
27 not evaluated. Fifth, we used the CES-D for the assessment of depression, and did not actually
28
29 treat patients with clinical depression. However, this evaluation of DEPs has been widely used in
30
31 many epidemiology studies, and the validity of the CES-D has been sufficiently established. Sixth,
32
33 we did not adjust for the increased probability of a Type I error, because this was an exploratory
34
35 study.

削除: depression

削除: Finally, this study of race was limited to only Hispanics/Latinos. Further studies are needed among other races to generalize our findings.

5 Conclusion

36
37
38
39
40
41
42
43
44 NRS was a risk factor for incident DEPs, which includes a predictive ability for other
45
46 insomnia-related symptoms. Our results suggest the importance of focusing on NRS to develop
47
48 more effective public health strategies for preventing depression.
49
50
51
52
53
54
55
56
57
58
59
60

削除: We examined the predictive ability of insomnia-related symptoms, including NRS, for incident depression.

削除: depression

削除: the ability to predict

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(3438/3500 words)

删除: 96

For Peer Review

References

American Academy of Sleep Medicine. (2014). *International Classification of Sleep Disorders* (3rd ed.).

American Academy of Sleep Medicine.

Andresen, E. M., Malmgren, J. A., Carter, W. B., & Patrick, D. L. (1994, Mar-Apr). Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med*, *10*(2), 77-84.

Baglioni, C., Battagliese, G., Feige, B., Spiegelhalter, K., Nissen, C., Voderholzer, U., Lombardo, C., & Riemann, D. (2011, Dec). Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. *J Affect Disord*, *135*(1-3), 10-19.
<https://doi.org/10.1016/j.jad.2011.01.011>

Bernert, R. A., Turvey, C. L., Conwell, Y., & Joiner, T. E., Jr. (2014, Oct). Association of poor subjective sleep quality with risk for death by suicide during a 10-year period: a longitudinal, population-based study of late life. *JAMA Psychiatry*, *71*(10), 1129-1137.
<https://doi.org/10.1001/jamapsychiatry.2014.1126>

- 1
2
3
4
5
6
7
8
9
10
11
12
13 Carroll, J. E., Irwin, M. R., Levine, M., Seeman, T. E., Absher, D., Assimes, T., & Horvath, S. (2017,
14 2017/01/15/). Epigenetic Aging and Immune Senescence in Women With Insomnia Symptoms:
15 Findings From the Women's Health Initiative Study. *Biological Psychiatry*, *81*(2), 136-144.
16 <https://doi.org/https://doi.org/10.1016/j.biopsych.2016.07.008>
17
18
19
20
21
22
23
24 González, P., Nuñez, A., Merz, E., Brintz, C., Weitzman, O., Navas, E. L., Camacho, A., Buelna, C., Penedo,
25 F. J., Wassertheil-Smoller, S., Perreira, K., Isasi, C. R., Choca, J., Talavera, G. A., & Gallo, L. C.
26 (2017). Measurement properties of the Center for Epidemiologic Studies Depression Scale (CES-
27 D 10): Findings from HCHS/SOL. *Psychological assessment*, *29*(4), 372-381.
28 <https://doi.org/10.1037/pas0000330>
29
30
31
32
33
34
35
36
37
38 Hartz, A. J., Daly, J. M., Kohatsu, N. D., Stromquist, A. M., Jogerst, G. J., & Kukoyi, O. A. (2007,
39 2007/12/01/). Risk Factors for Insomnia in a Rural Population. *Annals of Epidemiology*, *17*(12),
40 940-947. <https://doi.org/https://doi.org/10.1016/j.annepidem.2007.07.097>
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13 James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F.,
 14
 15 Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R. S., Abebe, Z., Abera, S. F., Abil, O. Z.,
 16
 17 Abraha, H. N., Abu-Raddad, L. J., Abu-Rmeileh, N. M. E., Accrombessi, M. M. K., Acharya, D.,
 18
 19 Acharya, P., Ackerman, I. N., Adamu, A. A., Adebayo, O. M., Adekanmbi, V., Adetokunboh, O.
 20
 21 O., Adib, M. G., Adsuar, J. C., Afanvi, K. A., Afarideh, M., Afshin, A., Agarwal, G., Agesa, K. M.,
 22
 23 Aggarwal, R., Aghayan, S. A., Agrawal, S., Ahmadi, A., Ahmadi, M., Ahmadieh, H., Ahmed, M.
 24
 25 B., Aichour, A. N., Aichour, I., Aichour, M. T. E., Akinyemiju, T., Akseer, N., Al-Aly, Z., Al-
 26
 27 Eyadhy, A., Al-Mekhlafi, H. M., Al-Raddadi, R. M., Alahdab, F., Alam, K., Alam, T., Alashi, A.,
 28
 29 Alavian, S. M., Alene, K. A., Alijanzadeh, M., Alizadeh-Navaei, R., Aljunid, S. M., Alkerwi, A.
 30
 31 a., Alla, F., Allebeck, P., Alouani, M. M. L., Altirkawi, K., Alvis-Guzman, N., Amare, A. T.,
 32
 33 Aminde, L. N., Ammar, W., Amoako, Y. A., Anber, N. H., Andrei, C. L., Androudi, S., Anmut, M.
 34
 35 D., Anjomshoa, M., Ansha, M. G., Antonio, C. A. T., Anwari, P., Arabloo, J., Arauz, A., Aremu,
 36
 37 O., Ariani, F., Armoon, B., Ärmlöv, J., Arora, A., Artaman, A., Aryal, K. K., Asayesh, H., Asghar,
 38
 39 R. J., Ataro, Z., Atre, S. R., Ausloos, M., Avila-Burgos, L., Avokpaho, E. F. G. A., Awasthi, A.,
 40
 41 Ayala Quintanilla, B. P., Ayer, R., Azzopardi, P. S., Babazadeh, A., Badali, H., Badawi, A., Bali,
 42
 43 A. G., Ballesteros, K. E., Ballew, S. H., Banach, M., Banoub, J. A. M., Banstola, A., Barac, A.,
 44
 45 Barboza, M. A., Barker-Collo, S. L., Bärnighausen, T. W., Barrero, L. H., Baune, B. T., Bazargan-
 46
 47 Hejazi, S., Bedi, N., Beghi, E., Behzadifar, M., Behzadifar, M., Béjot, Y., Belachew, A. B., Belay,
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Y. A., Bell, M. L., Bello, A. K., Bensenor, I. M., Bernabe, E., Bernstein, R. S., Beuran, M.,
Beyranvand, T., Bhala, N., Bhattarai, S., Bhaumik, S., Bhutta, Z. A., Biadgo, B., Bijani, A., Bikbov,
B., Bilano, V., Bililign, N., Bin Sayeed, M. S., Bisanzio, D., Blacker, B. F., Blyth, F. M., Bou-Orm,
I. R., Boufous, S., Bourne, R., Brady, O. J., Brainin, M., Brant, L. C., Brazinova, A., Breitborde,
N. J. K., Brenner, H., Briant, P. S., Briggs, A. M., Briko, A. N., Britton, G., Brugha, T., Buchbinder,
R., Busse, R., Butt, Z. A., Cahuana-Hurtado, L., Cano, J., Cárdenas, R., Carrero, J. J., Carter, A.,
Carvalho, F., Castañeda-Orjuela, C. A., Castillo Rivas, J., Castro, F., Catalá-López, F., Cercy, K.
M., Cerin, E., Chaiah, Y., Chang, A. R., Chang, H.-Y., Chang, J.-C., Charlson, F. J., Chattopadhyay,
A., Chattu, V. K., Chaturvedi, P., Chiang, P. P.-C., Chin, K. L., Chitheer, A., Choi, J.-Y. J.,
Chowdhury, R., Christensen, H., Christopher, D. J., Cicuttini, F. M., Ciobanu, L. G., Cirillo, M.,
Claro, R. M., Collado-Mateo, D., Cooper, C., Coresh, J., Cortesi, P. A., Cortinovia, M., Costa, M.,
Cousin, E., Criqui, M. H., Cromwell, E. A., Cross, M., Crump, J. A., Dadi, A. F., Dandona, L.,
Dandona, R., Dargan, P. I., Daryani, A., Das Gupta, R., Das Neves, J., Dasa, T. T., Davey, G.,
Davis, A. C., Davitoiu, D. V., De Courten, B., De La Hoz, F. P., De Leo, D., De Neve, J.-W.,
Degefa, M. G., Degenhardt, L., Deiparine, S., Dellavalle, R. P., Demoz, G. T., Deribe, K., Dervenis,
N., Des Jarlais, D. C., Dessie, G. A., Dey, S., Dharmaratne, S. D., Dinberu, M. T., Dirac, M. A.,
Djalalinia, S., Doan, L., Dokova, K., Doku, D. T., Dorsey, E. R., Doyle, K. E., Driscoll, T. R.,
Dubey, M., Dubljanin, E., Duken, E. E., Duncan, B. B., Duraes, A. R., Ebrahimi, H., Ebrahimpour,

1
2
3
4
5
6
7
8
9
10
11
12
13 S., Echko, M. M., Edvardsson, D., Effiong, A., Ehrlich, J. R., El Bcheraoui, C., El Sayed Zaki, M.,
14
15 El-Khatib, Z., Elkout, H., Elyazar, I. R. F., Enayati, A., Endries, A. Y., Er, B., Erskine, H. E.,
16
17 Eshrati, B., Eskandarieh, S., Esteghamati, A., Esteghamati, S., Fakhim, H., Fallah Omrani, V.,
18
19 Faramarzi, M., Fareed, M., Farhadi, F., Farid, T. A., Farinha, C. S. E. s., Farioli, A., Faro, A., Farvid,
20
21 M. S., Farzadfar, F., Feigin, V. L., Fentahun, N., Fereshtehnejad, S.-M., Fernandes, E., Fernandes,
22
23 J. C., Ferrari, A. J., Feyissa, G. T., Filip, I., Fischer, F., Fitzmaurice, C., Foigt, N. A., Foreman, K.
24
25 J., Fox, J., Frank, T. D., Fukumoto, T., Fullman, N., Fürst, T., Furtado, J. M., Futran, N. D., Gall,
26
27 S., Ganji, M., Gankpe, F. G., Garcia-Basteiro, A. L., Gardner, W. M., Gebre, A. K., Gebremedhin,
28
29 A. T., Gebremichael, T. G., Gelano, T. F., Geleijnse, J. M., Genova-Maleras, R., Geramo, Y. C. D.,
30
31 Gething, P. W., Gezae, K. E., Ghadiri, K., Ghasemi Falavarjani, K., Ghasemi-Kasman, M.,
32
33 Ghimire, M., Ghosh, R., Ghoshal, A. G., Giampaoli, S., Gill, P. S., Gill, T. K., Ginawi, I. A.,
34
35 Giussani, G., Gnedovskaya, E. V., Goldberg, E. M., Goli, S., Gómez-Dantés, H., Gona, P. N.,
36
37 Gopalani, S. V., Gorman, T. M., Goulart, A. C., Goulart, B. N. G., Grada, A., Grams, M. E., Grosso,
38
39 G., Gugnani, H. C., Guo, Y., Gupta, P. C., Gupta, R., Gupta, R., Gupta, T., Gyawali, B., Haagsma,
40
41 J. A., Hachinski, V., Hafezi-Nejad, N., Haghparast Bidgoli, H., Hagos, T. B., Hailu, G. B., Haj-
42
43 Mirzaian, A., Haj-Mirzaian, A., Hamadeh, R. R., Hamidi, S., Handal, A. J., Hankey, G. J., Hao, Y.,
44
45 Harb, H. L., Harikrishnan, S., Haro, J. M., Hasan, M., Hassankhani, H., Hassen, H. Y., Havmoeller,
46
47 R., Hawley, C. N., Hay, R. J., Hay, S. I., Hedayatizadeh-Omran, A., Heibati, B., Hendrie, D.,
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Henok, A., Herteliu, C., Heydarpour, S., Hibstu, D. T., Hoang, H. T., Hoek, H. W., Hoffman, H. J.,
Hole, M. K., Homaie Rad, E., Hoogar, P., Hosgood, H. D., Hosseini, S. M., Hosseinzadeh, M.,
Hostiuc, M., Hostiuc, S., Hotez, P. J., Hoy, D. G., Hsairi, M., Htet, A. S., Hu, G., Huang, J. J.,
Huynh, C. K., Iburg, K. M., Ikeda, C. T., Ileanu, B., Ilesanmi, O. S., Iqbal, U., Irvani, S. S. N.,
Irvine, C. M. S., Islam, S. M. S., Islami, F., Jacobsen, K. H., Jahangiry, L., Jahanmehr, N., Jain, S.
K., Jakovljevic, M., Javanbakht, M., Jayatilleke, A. U., Jeemon, P., Jha, R. P., Jha, V., Ji, J. S.,
Johnson, C. O., Jonas, J. B., Jozwiak, J. J., Jungari, S. B., Jürisson, M., Kabir, Z., Kadel, R., Kahsay,
A., Kalani, R., Kanchan, T., Karami, M., Karami Matin, B., Karch, A., Karema, C., Karimi, N.,
Karimi, S. M., Kasaeian, A., Kassa, D. H., Kassa, G. M., Kassa, T. D., Kassebaum, N. J.,
Katikireddi, S. V., Kawakami, N., Karyani, A. K., Keighobadi, M. M., Keiyoro, P. N., Kemmer,
L., Kemp, G. R., Kengne, A. P., Keren, A., Khader, Y. S., Khafaei, B., Khafaie, M. A., Khajavi, A.,
Khalil, I. A., Khan, E. A., Khan, M. S., Khan, M. A., Khang, Y.-H., Khazaei, M., Khoja, A. T.,
Khosravi, A., Khosravi, M. H., Kiadaliri, A. A., Kiirithio, D. N., Kim, C.-I., Kim, D., Kim, P., Kim,
Y.-E., Kim, Y. J., Kimokoti, R. W., Kinfu, Y., Kisa, A., Kissimova-Skarbek, K., Kivimäki, M.,
Knudsen, A. K. S., Kocarnik, J. M., Kochhar, S., Kokubo, Y., Kolola, T., Kopec, J. A., Kosen, S.,
Kotsakis, G. A., Koul, P. A., Koyanagi, A., Kravchenko, M. A., Krishan, K., Krohn, K. J., Kuate
Defo, B., Kucuk Bicer, B., Kumar, G. A., Kumar, M., Kyu, H. H., Lad, D. P., Lad, S. D., Lafranconi,
A., Lalloo, R., Lallukka, T., Lami, F. H., Lansingh, V. C., Latifi, A., Lau, K. M.-M., Lazarus, J. V.,

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13 Leasher, J. L., Ledesma, J. R., Lee, P. H., Leigh, J., Leung, J., Levi, M., Lewycka, S., Li, S., Li,
 14
 15 Y., Liao, Y., Liben, M. L., Lim, L.-L., Lim, S. S., Liu, S., Lodha, R., Looker, K. J., Lopez, A. D.,
 16
 17 Lorkowski, S., Lotufo, P. A., Low, N., Lozano, R., Lucas, T. C. D., Lucchesi, L. R., Lunevicius,
 18
 19 R., Lyons, R. A., Ma, S., Macarayan, E. R. K., Mackay, M. T., Madotto, F., Magdy Abd El Razek,
 20
 21 H., Magdy Abd El Razek, M., Maghavani, D. P., Mahotra, N. B., Mai, H. T., Majdan, M.,
 22
 23 Majdzadeh, R., Majeed, A., Malekzadeh, R., Malta, D. C., Mamun, A. A., Manda, A.-L.,
 24
 25 Manguerra, H., Manhertz, T., Mansournia, M. A., Mantovani, L. G., Mapoma, C. C., Maravilla, J.
 26
 27 C., Marcenes, W., Marks, A., Martins-Melo, F. R., Martopullo, I., März, W., Marzan, M. B.,
 28
 29 Mashamba-Thompson, T. P., Massenburg, B. B., Mathur, M. R., Matsushita, K., Maulik, P. K.,
 30
 31 Mazidi, M., McAlinden, C., McGrath, J. J., McKee, M., Mehndiratta, M. M., Mehrotra, R., Mehta,
 32
 33 K. M., Mehta, V., Mejia-Rodriguez, F., Mekonen, T., Melese, A., Melku, M., Meltzer, M., Memiah,
 34
 35 P. T. N., Memish, Z. A., Mendoza, W., Mengistu, D. T., Mengistu, G., Mensah, G. A., Mereta, S.
 36
 37 T., Meretoja, A., Meretoja, T. J., Mestrovic, T., Mezerji, N. M. G., Miazgowski, B., Miazgowski,
 38
 39 T., Milllear, A. I., Miller, T. R., Miltz, B., Mini, G. K., Mirarefin, M., Mirrakhimov, E. M.,
 40
 41 Misganaw, A. T., Mitchell, P. B., Mitiku, H., Moazen, B., Mohajer, B., Mohammad, K. A.,
 42
 43 Mohammadifard, N., Mohammadnia-Afrouzi, M., Mohammed, M. A., Mohammed, S., Mohebi,
 44
 45 F., Moitra, M., Mokdad, A. H., Molokhia, M., Monasta, L., Moodley, Y., Moosazadeh, M., Moradi,
 46
 47 G., Moradi-Lakeh, M., Moradinazar, M., Moraga, P., Morawska, L., Moreno Velásquez, I.,
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

1
2
3
4
5
6
7
8
9
10
11
12
13 Morgado-Da-Costa, J., Morrison, S. D., Moschos, M. M., Mountjoy-Venning, W. C., Mousavi, S.
14
15 M., Mruts, K. B., Muche, A. A., Muchie, K. F., Mueller, U. O., Muhammed, O. S., Mukhopadhyay,
16
17 S., Muller, K., Mumford, J. E., Murhekar, M., Musa, J., Musa, K. I., Mustafa, G., Nabhan, A. F.,
18
19 Nagata, C., Naghavi, M., Naheed, A., Nahvijou, A., Naik, G., Naik, N., Najafi, F., Naldi, L., Nam,
20
21 H. S., Nangia, V., Nansseu, J. R., Nascimento, B. R., Natarajan, G., Neamati, N., Negoi, I., Negoi,
22
23 R. I., Neupane, S., Newton, C. R. J., Ngunjiri, J. W., Nguyen, A. Q., Nguyen, H. T., Nguyen, H. L.
24
25 T., Nguyen, H. T., Nguyen, L. H., Nguyen, M., Nguyen, N. B., Nguyen, S. H., Nichols, E.,
26
27 Ningrum, D. N. A., Nixon, M. R., Nolutshungu, N., Nomura, S., Norheim, O. F., Noroozi, M.,
28
29 Norrvig, B., Noubiap, J. J., Nouri, H. R., Nouroollahpour Shiadeh, M., Nowroozi, M. R., Nsoesie,
30
31 E. O., Nyasulu, P. S., Odell, C. M., Ofori-Asenso, R., Ogbo, F. A., Oh, I.-H., Oladimeji, O.,
32
33 Olagunju, A. T., Olagunju, T. O., Olivares, P. R., Olsen, H. E., Olusanya, B. O., Ong, K. L., Ong,
34
35 S. K., Oren, E., Ortiz, A., Ota, E., Otstavnov, S. S., Øverland, S., Owolabi, M. O., PA, M., Pacella,
36
37 R., Pakpour, A. H., Pana, A., Panda-Jonas, S., Parisi, A., Park, E.-K., Parry, C. D. H., Patel, S.,
38
39 Pati, S., Patil, S. T., Patle, A., Patton, G. C., Paturi, V. R., Paulson, K. R., Pearce, N., Pereira, D.
40
41 M., Perico, N., Pesudovs, K., Pham, H. Q., Phillips, M. R., Pigott, D. M., Pillay, J. D., Piradov, M.
42
43 A., Pirsahab, M., Pishgar, F., Plana-Ripoll, O., Plass, D., Polinder, S., Popova, S., Postma, M. J.,
44
45 Pourshams, A., Poustchi, H., Prabhakaran, D., Prakash, S., Prakash, V., Purcell, C. A., Purwar, M.
46
47 B., Qorbani, M., Quistberg, D. A., Radfar, A., Rafay, A., Rafiei, A., Rahim, F., Rahimi, K., Rahimi-

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13 Movaghar, A., Rahimi-Movaghar, V., Rahman, M., Rahman, M. H. u., Rahman, M. A., Rahman,
 14
 15 S. U., Rai, R. K., Rajati, F., Ram, U., Ranjan, P., Ranta, A., Rao, P. C., Rawaf, D. L., Rawaf, S.,
 16
 17 Reddy, K. S., Reiner, R. C., Reinig, N., Reitsma, M. B., Remuzzi, G., Renzaho, A. M. N.,
 18
 19 Resnikoff, S., Rezaei, S., Rezai, M. S., Ribeiro, A. L. P., Roberts, N. L. S., Robinson, S. R., Roever,
 20
 21 L., Ronfani, L., Roshandel, G., Rostami, A., Roth, G. A., Roy, A., Rubagotti, E., Sachdev, P. S.,
 22
 23 Sadat, N., Saddik, B., Sadeghi, E., Saeedi Moghaddam, S., Safari, H., Safari, Y., Safari-Faramani,
 24
 25 R., Safdarian, M., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sahraian, M. A., Sajadi, H. S., Salam,
 26
 27 N., Salama, J. S., Salamati, P., Saleem, K., Saleem, Z., Salimi, Y., Salomon, J. A., Salvi, S. S., Salz,
 28
 29 I., Samy, A. M., Sanabria, J., Sang, Y., Santomauro, D. F., Santos, I. S., Santos, J. V., Santric
 30
 31 Milicevic, M. M., Sao Jose, B. P., Sardana, M., Sarker, A. R., Sarrafzadegan, N., Sartorius, B.,
 32
 33 Sarvi, S., Sathian, B., Satpathy, M., Sawant, A. R., Sawhney, M., Saxena, S., Saylan, M.,
 34
 35 Schaeffner, E., Schmidt, M. I., Schneider, I. J. C., Schöttker, B., Schwebel, D. C., Schwendicke,
 36
 37 F., Scott, J. G., Sekerija, M., Sepanlou, S. G., Serván-Mori, E., Seyedmousavi, S., Shabaninejad,
 38
 39 H., Shafieesabet, A., Shahbazi, M., Shaheen, A. A., Shaikh, M. A., Shams-Beyranvand, M.,
 40
 41 Shamsi, M., Shamsizadeh, M., Sharafi, H., Sharafi, K., Sharif, M., Sharif-Alhoseini, M., Sharma,
 42
 43 M., Sharma, R., She, J., Sheikh, A., Shi, P., Shibuya, K., Shigematsu, M., Shiri, R., Shirkoohi, R.,
 44
 45 Shishani, K., Shiue, I., Shokraneh, F., Shoman, H., Shrime, M. G., Si, S., Siabani, S., Siddiqi, T.
 46
 47 J., Sigfusdottir, I. D., Sigurvinsdottir, R., Silva, J. P., Silveira, D. G. A., Singam, N. S. V., Singh,
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13 J. A., Singh, N. P., Singh, V., Sinha, D. N., Skiadaresi, E., Slepak, E. L. N., Sliwa, K., Smith, D.
 14
 15 L., Smith, M., Soares Filho, A. M., Sobaih, B. H., Sobhani, S., Sobngwi, E., Soneji, S. S., Soofi,
 16
 17 M., Soosaraei, M., Sorensen, R. J. D., Soriano, J. B., Soyiri, I. N., Sposato, L. A., Sreeramareddy,
 18
 19 C. T., Srinivasan, V., Stanaway, J. D., Stein, D. J., Steiner, C., Steiner, T. J., Stokes, M. A., Stovner,
 20
 21 L. J., Subart, M. L., Sudaryanto, A., Sufiyan, M. a. B., Sunguya, B. F., Sur, P. J., Sutradhar, I.,
 22
 23 Sykes, B. L., Sylte, D. O., Tabarés-Seisdedos, R., Tadakamadla, S. K., Tadesse, B. T., Tandon, N.,
 24
 25 Tassew, S. G., Tavakkoli, M., Taveira, N., Taylor, H. R., Tehrani-Banihashemi, A., Tekalign, T. G.,
 26
 27 Tekelemedhin, S. W., Tekle, M. G., Temesgen, H., Temsah, M.-H., Temsah, O., Terkawi, A. S.,
 28
 29 Teweldemedhin, M., Thankappan, K. R., Thomas, N., Tilahun, B., To, Q. G., Tonelli, M., Topor-
 30
 31 Madry, R., Topouzis, F., Torre, A. E., Tortajada-Girbés, M., Touvier, M., Tovani-Palone, M. R.,
 32
 33 Towbin, J. A., Tran, B. X., Tran, K. B., Troeger, C. E., Truelsen, T. C., Tsilimbaris, M. K., Tsoi,
 34
 35 D., Tudor Car, L., Tuzcu, E. M., Ukwaja, K. N., Ullah, I., Undurraga, E. A., Unutzer, J., Updike,
 36
 37 R. L., Usman, M. S., Uthman, O. A., Vaduganathan, M., Vaezi, A., Valdez, P. R., Varughese, S.,
 38
 39 Vasankari, T. J., Venketasubramanian, N., Villafaina, S., Violante, F. S., Vladimirov, S. K., Vlassov,
 40
 41 V., Vollset, S. E., Vosoughi, K., Vujcic, I. S., Wagnew, F. S., Waheed, Y., Waller, S. G., Wang, Y.,
 42
 43 Wang, Y.-P., Weiderpass, E., Weintraub, R. G., Weiss, D. J., Weldegebreal, F., Weldegewergs, K.
 44
 45 G., Werdecker, A., West, T. E., Whiteford, H. A., Widecka, J., Wijeratne, T., Wilner, L. B., Wilson,
 46
 47 S., Winkler, A. S., Wiyeh, A. B., Wiysonge, C. S., Wolfe, C. D. A., Woolf, A. D., Wu, S., Wu, Y.-
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

1
2
3
4
5
6
7
8
9
10
11
12
13 C., Wyper, G. M. A., Xavier, D., Xu, G., Yadgir, S., Yadollahpour, A., Yahyazadeh Jabbari, S. H.,

14 Yamada, T., Yan, L. L., Yano, Y., Yaseri, M., Yasin, Y. J., Yeshanch, A., Yimer, E. M., Yip, P.,

15 Yisma, E., Yonemoto, N., Yoon, S.-J., Yotebieng, M., Younis, M. Z., Youseffard, M., Yu, C.,

16 Zadnik, V., Zaidi, Z., Zaman, S. B., Zamani, M., Zare, Z., Zeleke, A. J., Zenebe, Z. M., Zhang, K.,

17 Zhao, Z., Zhou, M., Zodpey, S., Zucker, I., Vos, T., & Murray, C. J. L. (2018). Global, regional,

18 and national incidence, prevalence, and years lived with disability for 354 diseases and injuries

19 for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden

20 of Disease Study 2017. *The Lancet*, 392(10159), 1789-1858. <https://doi.org/10.1016/S0140->

21 6736(18)32279-7

22
23
24
25
26
27
28
29
30
31
32
33
34
35 Kaneita, Y., Ohida, T., Uchiyama, M., Takemura, S., Kawahara, K., Yokoyama, E., Miyake, T., Harano, S.,

36 Suzuki, K., & Fujita, T. (2006, Feb). The relationship between depression and sleep disturbances:

37 a Japanese nationwide general population survey. *J Clin Psychiatry*, 67(2), 196-203.

38 <https://doi.org/10.4088/jcp.v67n0204>

39
40
41
42
43
44
45
46
47 Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E.,

48 & Wang, P. S. (2003, Jun 18). The epidemiology of major depressive disorder: results from the

49 National Comorbidity Survey Replication (NCS-R). *Jama*, 289(23), 3095-3105.

1
2
3
4
5
6
7
8
9
10
11
12
13 <https://doi.org/10.1001/jama.289.23.3095>
14
15
16

17
18 LaVange, L. M., Kalsbeek, W. D., Sorlie, P. D., Avilés-Santa, L. M., Kaplan, R. C., Barnhart, J., Liu, K.,
19
20 Giachello, A., Lee, D. J., Ryan, J., Criqui, M. H., & Elder, J. P. (2010, 2010/08/01). Sample Design
21
22 and Cohort Selection in the Hispanic Community Health Study/Study of Latinos. *Annals of*
23
24 *Epidemiology*, 20(8), 642-649. <https://doi.org/https://doi.org/10.1016/j.annepidem.2010.05.006>
25
26

27
28
29 Leineweber, C., Kecklund, G., Janszky, I., Akerstedt, T., & Orth-Gomér, K. (2003, Feb). Poor sleep
30
31 increases the prospective risk for recurrent events in middle-aged women with coronary disease.
32
33 The Stockholm Female Coronary Risk Study. *J Psychosom Res*, 54(2), 121-127.
34
35 [https://doi.org/10.1016/s0022-3999\(02\)00475-0](https://doi.org/10.1016/s0022-3999(02)00475-0)
36
37

38
39
40 Levine, D. W., Kripke, D. F., Kaplan, R. M., Lewis, M. A., Naughton, M. J., Bowen, D. J., & Shumaker, S.
41
42 A. (2003, Jun). Reliability and validity of the Women's Health Initiative Insomnia Rating Scale.
43
44 *Psychological assessment*, 15(2), 137-148. <https://doi.org/10.1037/1040-3590.15.2.137>
45
46

47
48
49 Li, L., Wu, C., Gan, Y., Qu, X., & Lu, Z. (2016, Nov 5). Insomnia and the risk of depression: a meta-
50
51 analysis of prospective cohort studies. *BMC Psychiatry*, 16(1), 375.
52
53

1
2
3
4
5
6
7
8
9
10
11
12
13
14 <https://doi.org/10.1186/s12888-016-1075-3>
15
16
17

18 Matsumoto, T., Tabara, Y., Murase, K., Takahashi, Y., Setoh, K., Kawaguchi, T., Muro, S., Kadotani, H.,
19

20 Kosugi, S., Sekine, A., Yamada, R., Nakayama, T., Mishima, M., Matsuda, F., & Chin, K. (2017).
21

22 Combined association of clinical and lifestyle factors with non-restorative sleep: The Nagahama
23

24 Study. *PLoS One*, *12*(3), e0171849. <https://doi.org/10.1371/journal.pone.0171849>
25
26
27

28
29 Moldofsky, H. (1989, Nov). Nonrestorative sleep and symptoms after a febrile illness in patients with
30

31 fibrositis and chronic fatigue syndromes. *J Rheumatol Suppl*, *19*, 150-153.
32
33
34

35 Ohayon, M. M. (2005, Jan 10). Prevalence and correlates of nonrestorative sleep complaints. *Arch Intern*
36

37 *Med*, *165*(1), 35-41. <https://doi.org/10.1001/archinte.165.1.35>
38
39
40
41

42 Ohayon, M. M., & Hong, S.-C. (2002, 2002/07/01/). Prevalence of insomnia and associated factors in South
43

44 Korea. *Journal of Psychosomatic Research*, *53*(1), 593-600.
45

46 [https://doi.org/https://doi.org/10.1016/S0022-3999\(02\)00449-X](https://doi.org/https://doi.org/10.1016/S0022-3999(02)00449-X)
47
48
49
50

51 Ohayon, M. M., & Roth, T. (2001, Dec). What are the contributing factors for insomnia in the general
52
53
54

- 1
2
3
4
5
6
7
8
9
10
11
12
13 population? *J Psychosom Res*, 51(6), 745-755. [https://doi.org/10.1016/s0022-3999\(01\)00285-9](https://doi.org/10.1016/s0022-3999(01)00285-9)
- 14
15
16
17 Okamoto, M., Kobayashi, Y., Nakamura, F., & Musha, T. (2017, Nov-Dec). Association Between
18
19 Nonrestorative Sleep and Risk of Diabetes: A Cross-Sectional Study. *Behav Sleep Med*, 15(6),
20
21 483-490. <https://doi.org/10.1080/15402002.2016.1163701>
- 22
23
24
25
26 Organization, W. H. (2020, 30 January 2020). *Depression*. Retrieved 1 September from
27
28 <https://www.who.int/news-room/fact-sheets/detail/depression>
- 29
30
31
32
33 Parrino, L., Ferri, R., Bruni, O., & Terzano, M. G. (2012, Feb). Cyclic alternating pattern (CAP): the marker
34
35 of sleep instability. *Sleep Med Rev*, 16(1), 27-45. <https://doi.org/10.1016/j.smr.2011.02.003>
- 36
37
38
39
40 Patel, S. R., Weng, J., Rueschman, M., Dudley, K. A., Lored, J. S., Mossavar-Rahmani, Y., Ramirez, M.,
41
42 Ramos, A. R., Reid, K., Seiger, A. N., Sotres-Alvarez, D., Zee, P. C., & Wang, R. (2015, Sep 1).
43
44 Reproducibility of a Standardized Actigraphy Scoring Algorithm for Sleep in a US
45
46 Hispanic/Latino Population. *Sleep*, 38(9), 1497-1503. <https://doi.org/10.5665/sleep.4998>
- 47
48
49
50
51 Radloff, L. S. (1977, 1977). The CES-D scale : a self report depression scale for research in the general
52
53

1
2
3
4
5
6
7
8
9
10
11
12
13 population. *Appl Psychol Meas*, 1, 385-401. <https://ci.nii.ac.jp/naid/10021821342/>

14
15
16
17
18 Redline, S., Sotres-Alvarez, D., Loredo, J., Hall, M., Patel, S. R., Ramos, A., Shah, N., Ries, A., Arens, R.,
19
20 Barnhart, J., Youngblood, M., Zee, P., & Daviglius, M. L. (2014, Feb 1). Sleep-disordered breathing
21
22 in Hispanic/Latino individuals of diverse backgrounds. The Hispanic Community Health
23
24 Study/Study of Latinos. *Am J Respir Crit Care Med*, 189(3), 335-344.
25
26 <https://doi.org/10.1164/rccm.201309-1735OC>

27
28
29
30
31 Roth, T., Jaeger, S., Jin, R., Kalsekar, A., Stang, P. E., & Kessler, R. C. (2006, Dec 15). Sleep problems,
32
33 comorbid mental disorders, and role functioning in the national comorbidity survey replication.
34
35 *Biol Psychiatry*, 60(12), 1364-1371. <https://doi.org/10.1016/j.biopsych.2006.05.039>

36
37
38
39
40 Roth, T., Zammit, G., Lankford, A., Mayleben, D., Stern, T., Pitman, V., Clark, D., & Werth, J. L. (2010,
41
42 Apr). Nonrestorative sleep as a distinct component of insomnia. *Sleep*, 33(4), 449-458.
43
44 <https://doi.org/10.1093/sleep/33.4.449>

45
46
47
48
49 Sorlie, P. D., Avilés-Santa, L. M., Wassertheil-Smoller, S., Kaplan, R. C., Daviglius, M. L., Giachello, A. L.,
50
51 Schneiderman, N., Raji, L., Talavera, G., Allison, M., LaVange, L., Chambless, L. E., & Heiss, G.

1
2
3
4
5
6
7
8
9
10
11
12
13 (2010, 2010/08/01/). Design and Implementation of the Hispanic Community Health Study/Study
14 of Latinos. *Annals of Epidemiology*, 20(8), 629-641.
15
16 <https://doi.org/https://doi.org/10.1016/j.annepidem.2010.03.015>
17
18

19
20
21
22 Stone, K. C., Taylor, D. J., McCrae, C. S., Kalsekar, A., & Lichstein, K. L. (2008, Aug). Nonrestorative
23 sleep. *Sleep Med Rev*, 12(4), 275-288. <https://doi.org/10.1016/j.smrv.2007.12.002>
24
25

26
27
28
29 Terzano, M. G., Parrino, L., Smerieri, A., Chervin, R., Chokroverty, S., Guilleminault, C., Hirshkowitz, M.,
30 Mahowald, M., Moldofsky, H., Rosa, A., Thomas, R., & Walters, A. (2001, Nov). Atlas, rules, and
31 recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. *Sleep Med*,
32 2(6), 537-553. [https://doi.org/10.1016/s1389-9457\(01\)00149-6](https://doi.org/10.1016/s1389-9457(01)00149-6)
33
34
35
36

37
38
39 Terzano, M. G., Parrino, L., Spaggiari, M. C., Palomba, V., Rossi, M., & Smerieri, A. (2003, Sep). CAP
40 variables and arousals as sleep electroencephalogram markers for primary insomnia. *Clin*
41 *Neurophysiol*, 114(9), 1715-1723. [https://doi.org/10.1016/s1388-2457\(03\)00136-6](https://doi.org/10.1016/s1388-2457(03)00136-6)
42
43
44
45

46
47
48
49 Tononi, G., & Cirelli, C. (2006, Feb). Sleep function and synaptic homeostasis. *Sleep Med Rev*, 10(1), 49-
50 62. <https://doi.org/10.1016/j.smrv.2005.05.002>
51
52
53

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16 Tononi, G., & Cirelli, C. (2014, Jan 8). Sleep and the price of plasticity: from synaptic and cellular
17
18 homeostasis to memory consolidation and integration. *Neuron*, *81*(1), 12-34.
19
20 <https://doi.org/10.1016/j.neuron.2013.12.025>
21
22

23
24 van der Helm, E., Yao, J., Dutt, S., Rao, V., Saletin, J. M., & Walker, M. P. (2011, Dec 6). REM sleep
25
26 depotentiates amygdala activity to previous emotional experiences. *Curr Biol*, *21*(23), 2029-2032.
27
28 <https://doi.org/10.1016/j.cub.2011.10.052>
29
30

31
32
33 Wittayanukorn, S., Qian, J., & Hansen, R. A. (2014, May-Jun). Prevalence of depressive symptoms and
34
35 predictors of treatment among U.S. adults from 2005 to 2010. *Gen Hosp Psychiatry*, *36*(3), 330-
36
37 336. <https://doi.org/10.1016/j.genhosppsy.2013.12.009>
38
39

40
41
42 Wong, M. L., & Licinio, J. (2001, May). Research and treatment approaches to depression. *Nat Rev*
43
44 *Neurosci*, *2*(5), 343-351. <https://doi.org/10.1038/35072566>
45
46

47
48
49 Yokoyama, E., Kaneita, Y., Saito, Y., Uchiyama, M., Matsuzaki, Y., Tamaki, T., Munezawa, T., & Ohida, T.
50
51 (2010, Dec). Association between depression and insomnia subtypes: a longitudinal study on the
52
53

1
2
3
4
5
6
7
8
9
10
11
12
13 elderly in Japan. *Sleep*, 33(12), 1693-1702. <https://doi.org/10.1093/sleep/33.12.1693>

14
15
16
17
18 Zhang, G. Q., Cui, L., Mueller, R., Tao, S., Kim, M., Rueschman, M., Mariani, S., Mobley, D., & Redline,
19
20 S. (2018, Oct 1). The National Sleep Research Resource: towards a sleep data commons. *J Am*
21
22 *Med Inform Assoc*, 25(10), 1351-1358. <https://doi.org/10.1093/jamia/ocy064>

23
24
25
26
27 Zhang, J., Lam, S.-P., Li, S. X., Li, A. M., & Wing, Y.-K. (2012, 2012/06/01/). The longitudinal course and
28
29 impact of non-restorative sleep: A five-year community-based follow-up study. *Sleep Medicine*,
30
31 13(6), 570-576. <https://doi.org/https://doi.org/10.1016/j.sleep.2011.12.012>

Table 1. Prevalence of incident depression by participant demographics.

		All (N=1196)		With incident depression (N=235)		Without incident depression (N=961)		Prevalence of depression (%)	p	
		N	(%)	N	(%)	N	(%)			
Insomnia	WHIIRS <9	843	70	138	59	705	73	16%	<0.001	***
	WHIIRS ≥9	353	30	97	41	256	27	28%		
Gender	Men	480	40	79	34	401	42	17%	0.023	*
	Female	716	60	156	66	560	58	22%		
Age (years)	18–29	182	15	34	15	148	15	19%	0.215	
	30–39	172	14	27	12	145	15	16%		
	40–49	375	31	67	29	308	32	18%		
	50–59	371	31	84	36	287	30	23%		
	60–64	96	8	23	10	73	8	24%		
BMI (kg/m ²)	<18.5	9	1	4	2	5	1	44%	0.11	
	≥18.5–25	221	19	48	20	173	18	22%		
	≥25	966	81	183	78	783	82	19%		
Site	Bronx	300	25	62	26	238	25	21%	0.025	*
	Chicago	306	26	76	32	230	24	25%		
	Miami	392	33	63	27	329	34	16%		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

	San Diego	198	17	34	15	164	17	17%		
Income (USD)	<30,000	760	64	159	68	601	63	21%	0.073	
	≥30,000	383	32	62	26	321	33	16%		
	Not reported	53	4	14	6	39	4	26%		
Education	Less than HS	347	29	90	38	257	27	26%	<0.001	***
	HS and more than HS	849	71	145	62	704	73	17%		
Marital status	Single	325	27	65	28	260	27	20%	0.407	
	Married or living with a partner	669	56	124	53	545	57	19%		
	Separated, divorced, or widower	202	17	46	19	156	16	23%		
Alcohol use	Never	249	21	55	23	194	20	22%	0.205	
	Former	392	33	83	35	309	32	21%		
	Current	555	46	97	41	458	48	18%		
Cigarette use	Never	748	63	136	58	612	64	18%	0.002	**
	Former	246	21	41	17	205	21	17%		
	Current	202	17	58	25	144	15	29%		
Sleeping medication use	Not, in the past 4 weeks	1063	89	200	85	863	90	19%	0.04	*
	Yes, in the past 4 weeks	133	11	35	15	98	10	26%		
Obstructive sleep apnea (AHI ≥15)	OSA ₋	1091	91	216	92	875	91	20%	0.675	
	OSA ₊	105	9	19	8	86	9	18%		
Sleep duration (h)	<6	78	7	18	8	60	6	23%	0.547	
	≥6 to 7	189	16	39	17	150	16	21%		

削除: +

削除: to 50

削除: -

	≥7 to 8	374	31	63	27	311	32	17%	
	≥8 to 9	326	27	69	29	257	27	21%	
	≥9	229	19	46	20	183	19	20%	
Follow-up years	1	386	32	85	36	301	31	22%	0.154
	2	810	68	150	64	660	69	19%	

*p<0.05, **p<0.01, ***p<0.001.

Abbreviations: WHIIRS, Women's Health Initiative Insomnia Rating Scale; BMI, body mass index; HS, high school; USD, United States dollar; AHI, apnea-hypopnea index.

Table 2. Prevalence of insomnia-related symptoms by age and gender.

		Difficulty initiating sleep ^{a,b}	Difficulty maintaining sleep ^a	Early morning awakening ^a	Difficulty returning to sleep ^a	Nonrestorative sleep
All	18–29	30%	41%	30%	24%	9%
	30–39	31%	49%	34%	27%	11%
	40–49	32%	49%	38%	26%	12%
	50–59	41%	60%	45%	37%	12%
	60–64	40%	59%	43%	42%	12%
	Total	35%	52%	39%	31%	11%
Male (N=480)	18–29	37%	39%	33%	25%	13%
	30–39	32%	54%	37%	31%	6%
	40–49	29%	47%	43%	28%	10%
	50–59	30%	61%	39%	29%	10%
	60–64	16%	49%	27%	24%	5%
	Total	30%	51%	38%	28%	10%
Female (N=716)	18–29	25%	43%	28%	22%	6%
	30–39	30%	46%	33%	24%	13%
	40–49	33%	51%	35%	26%	13%
	50–59	49%	60%	49%	43%	13%
	60–64	54%	66%	53%	53%	15%
	Total	38%	53%	39%	33%	12%

^asignificantly different among age groups, ^bsignificantly different between genders.

削除: 改ページ

削除: Table 3. Spearman correlation coefficients among insomnia-related symptoms. ↵

... 2

Table 3 Incident depression and insomnia-related symptoms in the logistic regression analysis.

N=1196	Crude OR		Adjusted 1		Adjusted 2		p
	(95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	
Difficulty initiating sleep	1.6 (1.2–2.1)	<0.01 **	1.4 (1.0–1.9)	0.042 *	0.9 (0.6–1.4)	0.699	
Difficulty maintaining sleep	1.6 (1.2–2.1)	<0.01 **	1.4 (1.0–1.9)	0.024 *	1.1 (0.8–1.6)	0.501	
Early morning awakening	1.5 (1.1–2.0)	<0.01 **	1.4 (1.0–1.9)	0.031 *	1.0 (0.7–1.4)	0.943	
Difficulty returning to sleep	1.9 (1.4–2.5)	<0.001 ***	1.8 (1.3–2.4)	<0.001 ***	1.5 (1.0–2.2)	0.071	
Nonrestorative sleep	2.5 (1.7–3.7)	<0.001 ***	2.6 (1.7–3.9)	<0.001 ***	2.2 (1.4–3.5)	0.001 **	

*p<0.05, **p<0.01, ***p<0.001

Abbreviations: OR, odds ratio; CI, confidence interval.

Adjusted 1: age, gender, BMI (body mass index), field center, annual household income, years of education, marital status, alcohol use, cigarette use, sleep medication use, OSA (obstructive sleep apnea), sleep duration, follow-up years.

Adjusted 2: Adjusted 1 + difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, difficulty returning to sleep, nonrestorative sleep.

削除: 4

削除: R

削除: R

削除: R

削除: <

削除: relative risk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Flowchart of the present study.



削除: Sample f

削除: ←
←
←
←
←

For Peer Review

1
2
3
4
5
6 ページ 10: [1] 削除 作成者
7
8
9

10
11
12
13 ページ 45: [2] 削除 作成者
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Visit 1 (2008–2010)
HCHS/SOL
n=16,415

Visit 2 (2010–2013)
Sueño Ancillary Study
n=2,252

1,912 consented to
share their data

1,196 included in
the present study

Screening criteria for Visit 2 (2010–2013)

1. Those aged 18 to 64 years
2. Those who had AHI <50 events per hour at V1
3. Those who had no narcolepsy diagnosis
4. Those who had never been treated for obstructive sleep apnea
5. Able to converse in either English or Spanish

Exclusion criteria (n=excluded subjects)

1. Follow-up period <365 days (n=33)
2. Incomplete data for covariates and WHIIRS (n=118)
3. No data for AHI at V1 (n=27)
4. Incomplete data for the CES-D 10 at both V1 and V2 (n=20)
5. Having depression at V1 (n=518).